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Since its discovery in the early 90s, a cornucopia of biological activities has been attributed to the 
IFI16 protein, including cell cycle regulation, tumor suppression, apoptosis, DNA damage signaling, 
virus sensing, and virus restriction. In addition, aberrant IFI16 expression and release in the 
extracellular space has been reported in a series of inflammatory conditions. The current hypothesis 
is that overexpression of the IFI16 protein occurs in tissue compartments where it is not 
physiologically expressed during inflammation. The ensuing release of the IFI16 protein into the 
extracellular space may allow it to behave like a damage-associated molecular pattern (DAMP) that 
signals through the Toll-like receptor 4 (TLR4) triggering inflammation by itself or through 
interaction with exogenous molecules, e.g., lipopolysaccharide (LPS). Pull down assays and ELISA 
were used to characterize IFI16 binding activity to LPS. The human monocytic cell line THP-1 and 
the renal carcinoma cell line 786-O, and the murine macrophages RAW 264.7 were used as target 
cells to define IFI16-induced proinflammatory activity. Co-immunoprecipitation (co-IP), surface 
plasmon resonance (SPR), and silencing experiments were used to define IFI16 signaling. We show 
that the IFI16 HINB domain binds to the lipid A moiety of either high or weak TLR4 agonist LPS 
variants. Treatment of THP-1, 786-O, or RAW 264.7 cells with IFI16 led to increased production of 
proinflammatory cytokines, which was further enhanced when IFI16 was pre-complexed with sub-
toxic doses of high TLR4 agonist LPS but not low agonists. Silencing of TLR4/MD-2 or MyD88 
abolished cytokine production. These findings alongside with other in vitro binding experiments 
indicate that PYRIN domain of IFI16 interacts and signals through TLR4. Collectively, our data 
provide compelling evidence that: i) IFI16 is a DAMP that triggers inflammation through the 
TLR4/MD2-MyD88 pathway; and ii) its activity is strongly enhanced upon binding to LPS variants 
regarded as full TLR4 activators. These data strengthen the notion that extracellular IFI16 functions 
as DAMP and point to new pathogenic mechanisms involving the crosstalk between IFI16 and 












Interferons (IFNs) are pleiotropic cytokines that are important regulators of immunity and 
inflammation. Interferons trigger transcription of diverse genes influencing protein synthesis 
(both cellular and viral), autophagy, apoptosis, angiogenesis and innate and adaptive immunity 
(Borden et al., 2007). There are three major types of IFN: type I IFN (such as IFN-α and IFN-β), 
type II IFN (IFN-γ) and type III IFN (IFN-λ). IFN families are distinguished by their sequence 
identity, the nature and distribution of cognate receptors and, to a lesser extent, their inducing 
stimulus and cell of origin (Ivashkiv, 2018; Ivashkiv and Donlin, 2014; Wack et al., 2015). IFN 
bind specific cell-surface receptors expressed on most cell types and signal via pathways using 
the Janus family of tyrosine kinases (Jaks) and signal transducers and activators of transcription 
(STATs) to activate gene expression (Fig 1). Elevated production of IFNs during infection and in 
autoimmune diseases results in increased expression of target genes, most typically canonical 
interferon-stimulated genes (ISGs), in diseased tissues and often in circulating blood cells, in a 
pattern of expression defined as an IFN signature (Barrat et al., 2019). Canonical ISGs are defined 
as genes transcriptionally activated by IFNs, as identified by transcriptomic analysis of IFN-
stimulated cells, and they typically are directly activated by transcription factors of the STAT 
family. The presence of an IFN signature is often considered a hallmark of certain autoimmune 








Fig 1. IFN signaling pathways. Interferons of different type engage different receptors. Type II interferon receptor is a 
tetramer while type I and III interferon receptor is a dimer. Adapted from MacMicking, 2012. 
 
1.2. The PYHIN gene family 
One family of the IFN-stimulated genes is the PYHIN gene family. The PYHIN genes were 
firstly identified as a cluster on syntenic genomic region of mouse and human chromosome 1 and 
were named mouse Ifi200 (interferon inducible) (Deschamps et al., 2003) and human HIN-200 
(hematopoietic, interferon-inducible nuclear proteins with a 200 amino acid repeat) (Ludlow et 
al., 2005). Then, they have been annotated as the PYHIN family, acknowledging the defining 
features of an N-terminal PYRIN domain and C-terminal HIN domain. Four PYHIN protein have 
been identified in humans (IFI16, MNDA, AIM2, and IFIX), and seven in mouse (p202, p203, 
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p204, p205, p206, Aim2/p210, and Mndal), as well as a number of predicted proteins (Fig 2) 
(Cridland et al., 2012; Landolfo et al., 1998; Schattgen and Fitzgerald, 2011).  
 
Fig 2. The human and murine PYHIN protein families. The PYHIN proteins consist of an N-terminal pyrin domain 
(PYD or PYRIN) and one or more HIN-200 domains, which can be one of 3 subtypes (HINA, HINB, or HINC) based on 
their sequence (Schattgen and Fitzgerald, 2011). 
 
All the members of the PYHIN family contains one or two partially conserved repeats of 200-
amino acid residues (HIN domains) at the C-terminus, which have been characterized into three 
subtypes termed A, B, and C according to consensus motifs (Ludlow et al., 2005). Within the HIN 
domains, there are at least two conserved motifs, the conserved MFHATVAT motif and the 
LxCxE pRb-binding motif, that have been shown to mediate protein-protein interactions. The 
high degree of conservation of this motifs may point to a functional role in mediating the 
8 
 
biological activities of the members of the PYHIN family (Asefa, 2004). MNDA, mndal, and 
IFIX contain a single HINA domain, whereas IFI16, p202, and p204 have a HINA and HINB 
domain. p203 has a single HINB domain, whereas AIM2 has a single HINC domain. The HIN 
domains are DNA-binding domains. The structural mechanism of DNA binding by HIN-200 
domains was firstly described in 2005 by Albrecht and colleagues (Albrecht et al., 2005) using 
computational analysis which predicted the presence of two oligonucleotide/oligosaccharide 
(OB) folds, similar to that observed in the human replication protein A (RPA). This was later 
confirmed in the solved structure of the IFI16 HINA domain (Liao et al., 2011)  (PDB: 2OQ0). 
Further biophysical analysis determined 2 OB folds in the IFI16 HINA domain, which had a 
higher affinity for single-stranded DNA (ssDNA) compared with double-stranded DNA 
(dsDNA), and could wrap, stretch and form oligomers with ssDNA (Yan et al., 2008). However, 
in subsequent studies the IFI16 HINB domain alone was demonstrated to be able to bind to 
dsDNA with relatively high affinity, which was further increased when both HIN domains were 
present (Ni et al., 2016; Unterholzner et al., 2010). 
The N-terminus of the PYHIN proteins, with the exception of p202, contains a PYRIN 
domain. The PYRIN domain (also known as PYD, DAPIN or PAAD domain) is a death domain 
(DD) protein fold that forms homotypic interactions with other PYRIN-containing proteins to 
form higher complexes with known roles in inflammation, apoptosis, and the cell cycle (Chu et 
al., 2015). The most studied role of PYRIN domains relates to their ability to engage protein 
complexes referred to as “inflammasomes”. These are multiprotein oligomers that form upon 
PYRIN-PYRIN interaction with the adaptor molecule apoptosis-associated speck-like protein 
containing a CARD (ASC) which then which then recruits pro-caspase-1 via its caspase 
recruitment domain (CARD) domain and activates the effector caspase through proteolytic 
cleavage. The activation of the inflammasome promotes proteolytic cleavage, maturation, and 
secretion of pro-inflammatory cytokines interleukin 1β (IL-1β) and interleukin 18 (IL-18) (Broz 
and Dixit, 2016). 
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The PYHIN proteins have been shown to localize to the nucleus and with a few exceptions to 
the cytoplasm. IFI16, IFIX, MNDA, p204, and mndal have either a monopartite nuclear 
localization sequence (NLS), bipartite NLS, or both, and are primarily located within the nucleus 
(Ludlow et al., 2005). Relocalization of these proteins from the nucleus to the cytosol can occur 
following stimulation. In contrast, AIM2 and p202 lack an NLS and are predominantly if not 
exclusively localized to the cytoplasm.  
The PYHIN proteins have been implicated in regulating growth and cell differentiation due 
to their tissue-specific inducibility by IFN treatment. The IFI16, p202, and p204 nuclear 
phosphoproteins are relatively well characterized with respect to their role in IFN action: these 
proteins are demonstrated to participate in the inhibition of cell cycle progression, modulation of 
differentiation, and cell survival. Generally, IFI-200 proteins are thought to act as scaffolds to 
assemble large protein complexes involved in the regulation of transcription (Ludlow et al., 2005). 
Another important role of some PYHIN proteins is to act as pattern recognition receptors (PRRs). 
PRRs serve as sensors for monitoring the extracellular and intracellular compartments for signs 
of infection or tissue injury. These PRRs, which are responsible for the detection of pathogen 
associated molecular patterns (PAMPs) which signal the presence of a pathogen, and damage 
associated molecular patterns (DAMPs) which signal tissue injury, include the Toll-like receptors 
(TLRs), the retinoic acid inducible gene-like receptors (RLRs), the nucleotide oligomerization 
domain-like receptors (NLRs), and the AIM2-like receptors (ALRs) (Kawai and Akira, 2009; 
Unterholzner et al., 2010). The ALRs are AIM2, p204 and IFI16. 
 
1.3. The human interferon-inducible protein 16 – IFI16 
IFI16 was originally identified by Trapani et al. as a gene that is constitutively expressed in 
human lymphoid cell lines and is inducible in myeloid cell lines after IFN-γ treatment or 
differentiating stimuli (Trapani et al., 1994). IFI16, as the other members of PYHIN family, 
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displays a PYRIN domain at its N-terminus, suggesting a role for this protein in the apoptotic 
pathway by regulating the activity of certain transcription factors in the nucleus, which are 
involved in the commitment to cell death. IFI16 also possesses both the HINA and HINB 
domains, which are separated by a 116 amino-acid spacer, a serine–threonine–proline (S/T/P)-
rich spacer region. The size of the spacer region in IFI16 is regulated by mRNA splicing and can 
contain one, two, or three copies of the highly conserved 56-aa S/T/P/ domain (Fig 3). Three IFI16 
isoforms (designated A, B, and C) arise due to alternative RNA splicing in the exons encoding 
the S/T/P domain, with the isoform B displaying the most abundant expression (Johnstone et al., 
1998).  
 
Fig 3. Domain organization of the IFI16 protein. The numbers represent the amino acid positions based on NCBI 
Reference Sequence NP_005522. From the N- to the C-terminal (left to right), IFI16 comprises a PYRIN domain involved 
in protein-protein interaction, and two hematopoietic interferon-inducible nuclear protein with 200-amino-acid repeats 
(HINA and HINB) domains, which are a hallmark of the absent in melanoma 2-like receptors (ALRs). S/T/P = 
serine/threonine/ proline-rich repeats, which are regulated by alternative mRNA splicing. Adapted from Caneparo et al., 
2018. 
 
IFI16 is expressed in CD34+ myeloid precursor cells and remains strongly expressed within 
monocyte precursors, peripheral blood monocytes, and throughout lymphoid development 
(Dawson et al., 1998). Following IFN-treatment, IFI16 localizes within the nucleolus and the 
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nucleoplasm of human cells. This nuclear import is mediated by a bipartite nuclear localization 
sequence (NLS) located at the N-terminus of the protein (Li et al., 2012). In addition to its 
expression in the hematopoietic system, immunohistochemical analysis of IFI16 expression in 
normal human tissues revealed that it is expressed in a highly restricted pattern in selected cells 
within certain organs  (Gariglio et al., 2002; Wei et al., 2003). IFI16 was found in epithelial cells 
of the skin, gastrointestinal tract, urogenital tract, and glands and ducts of breast tissues. 
Prominent IFI16 expression was seen in stratified squamous epithelia, particularly intense in basal 
cells in the proliferating compartments, whereas it gradually decreases in a more differentiated 
suprabasal compartment. In the underlying dermis, staining of connective tissue was restricted to 
scattered fibroblasts. In addition, all vascular endothelial cells from both blood and lymph vessels 
strongly expressed IFI16. 
IFI16 participates in the inhibition of cell cycle progression and in the regulation of apoptosis. 
IFI16 overexpression can result in decreased cell proliferation and a block in the cell cycle 
progression at the G1-S phase transition. IFI16-mediated growth arrest seems to be mediated by 
its interaction with p53 and pRb (Aglipay et al., 2003; Liao et al., 2011). Indeed, prostate cancer 
cell lines expressing functional p53 and pRb were significantly more sensitive to the 
antiproliferative activity of IFI16 (Xin et al., 2003). IFI16 has also been identified as an essential 
growth-specific effector of the cell extrinsic growth–inhibitory pathway of Ras/Raf signaling in 
medullary thyroid carcinoma cells (Kim et al., 2005). Finally, IFI16 expression has been found 
deregulated in several forms of human cancer (Azzimonti et al., 2004; Fujiuchi et al., 2004; Xin 
et al., 2003). Evaluation of some features of in vitro angiogenesis, namely chemotaxis, matrigel 
invasion, tube morphogenesis, and cell cycle progression, has demonstrated that IFI16 
overexpression impairs tube morphogenesis and proliferation of human endothelial cells 
(Raffaella et al., 2004). Altogether, these results point to a role for IFI16 in the regulation of cell 
growth, differentiation, and angiogenesis. 
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IFI16 is also implicated in inflammation and immune response. Not only the IFN-γ but also 
other pro-inflammatory cytokines such us IL-1β and TNFα can significantly induce IFI16 
expression (Mondini et al., 2007). Of note, anti-inflammatory cytokines (e.g., IL-4, IL-10, IL-13, 
and IL-17) failed to induce IFI16 expression. In addition to that, Gugliesi et al., reported that 
IFI16 is overexpressed in primary human umbilical vein endothelial cells (HUVEC) by oxidative 
stress (Gugliesi et al., 2005). Moreover, gene array analysis of IFI16 overexpressing HUVEC 
revealed an increased expression of genes involved in the regulation of the immune system 
(Caposio et al., 2007). IFI16 triggered the expression of adhesion molecules such as intercellular 
adhesion molecule-1 (ICAM-1) and E-selectin or chemokines such as IL-8 and monocyte 
chemoattractant protein-1 (MCP-1). Treatment of cells with short hairpin RNA targeting IFI16 
significantly inhibited ICAM-1 induction by IFN-γ and TNFα, demonstrating that IFI16 is 
involved in proinflammatory gene stimulation by IFN-γ and TNFα. Finally, functional analysis 
of the ICAM-1 promoter demonstrated that NF-kB is the main mediator of IFI16-driven gene 
induction (Caposio et al., 2007; Sponza et al., 2009). 
Regarding the role of IFI16 as a DNA sensor for intracellular DNA, many studies came out 
after it was firstly identified as an ALR (Unterholzner et al., 2010). IFI16 is unique, as it can 
shuttle between the cytoplasm and the nucleus, and can sense DNA derived from various 
pathogens, such as dsDNA from herpes simplex virus 1 (HSV-1), Kaposi sarcoma-associated 
herpesvirus (KSHV), human cytomegalovirus (HCMV), and ssDNA or dsDNA from bacteria, 
depending on the types of host cells and pathogens (Li et al., 2012; Veeranki and Choubey, 2012). 
Unlike AIM2, IFI16 predominantly localizes in the nucleus in most types of cells, acting as DNA 
sensor by detecting pathogenic DNA, and then triggering innate immune response against 
pathogen invasion by activation of cytoplasmic inflammasome and innate signaling pathways. 
Mechanistically, upon HSV-1 infection, IFI16 mainly detects HSV-1 genomic DNA in the 
nucleus and then translocates to the cytoplasm where cooperates with cyclic GMP-AMP synthase 
(cGAS) to activate the endoplasmic reticulum protein stimulator of interferon genes (STING) to 
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induce the expression of type I IFN through activating TBK1-IRF3 and NF-κB signaling 
pathways (Almine et al., 2017; Iqbal et al., 2016). In addition, during KSHV infection, nuclear 
IFI16 senses and binds to viral dsDNA, and then recruits the adaptor protein ASC, and 
procaspase-1 to form an activated inflammasome. Subsequently, the IFI16-inflammasome 
translocates to the cytoplasm where the proteolysis of inactivated procaspase-1 into activated 
caspase-1 and cleavage of IL-1β and IL-18 occur (Kerur et al., 2011; Singh et al., 2013). However, 
the detailed mechanisms for IFI16-mediated nuclear pathogenic DNA sensing and activation of 
STING and inflammasome in cytoplasm remain controversial. No defect in type I interferon 
production was found once knockout of IFI16 in human primary fibroblasts in response to HCMV 
infection (Gray et al., 2016). This may be due to specific cell types and species of virus used. 
Indeed, while similar activation of STING has been shown in macrophages and keratinocytes 
upon viral infection, IFI16 increases cyclic guanosine monophosphate-adenosine monophosphate 
(cGAMP) production by cGAS only in macrophages, indicating cell specific roles for IFI16 in 
cooperating with the cGAS pathway. In CD4+ T cells, HIV proviral DNA detection by IFI16 has 
a different outcome. Here IFI16 forms an inflammasome with ASC to activate caspase-1-
dependent pyroptotic cell death, resulting in abortive infection of these cells, thus promoting 
clinical progression of the acquired immune deficiency syndrome (AIDS) (Monroe et al., 2014). 
Indeed, silencing of IFI16 or ASC by shRNA or caspase-1 inhibition rescued CD4+ T cells from 
death. This discovery may explain how CD4+ T cells die during HIV infection. IFI16 can also 
restrict viral genomic replication as a transcriptional regulator through epigenetic modifications. 
IFI16 promotes the loading of nucleosomes and the addition of heterochromatin marks on infected 
cell protein 0 (ICP0)-null HSV-1 chromatin by modulating repressive histone modifications to 
restrict viral replication (Johnson et al., 2014; Orzalli et al., 2013). Upon KSHV infection and 
latency, IFI16 recruits the H3K9 methyltransferase SUV39H1 and GLP to the KSHV genome for 
silencing of KSHV lytic genes (Roy et al., 2019). Similar to that, after human papilloma virus 
(HPV) infection, IFI16 promotes the addition of heterochromatin marks and the reduction of 
14 
 
euchromatin marks on viral chromatin at both early and late promoters, thus reducing both viral 
replication and transcription. Finally, acting as a restriction factor, IFI16 blocks the binding of 
transcription factor Sp1 to the promoter region of viral DNA polymerase gene (UL54), restricting 
viral genome replication during HCMV infection (Gariano et al., 2012). To summarize, IFI16 has 
four potentially distinct mechanisms to restrict viral infections, (1) activation of the cGAS-
STING-IFN pathway, (2) formation of inflammasomes, (3) epigenetic silencing of viral 
promoters, (4) limiting access to host factors required for viral replication such as Sp1. This 
explains why IFI16 is such a frequent target of immune evasion by many different viruses (Chan 
and Gack, 2016). The protein pUL83 from HCMV binds IFI16 and blocks IFI16 oligomerization, 
thus preventing the activation of the STING-TBK1-IRF3 pathway  (Li et al., 2013), while the 
protein pUL97 promotes IFI16 phosphorylation and delocalization to the cytoplasm of HCMV-
infected cells (Dell’Oste et al., 2014). ICP0 from HSV targets IFI16 for degradation (Orzalli et 
al., 2012), while it was recently reported that the E7 protein from HPV recruits the E3 ligase 
TRIM21 to ubiquitinate and degrade IFI16 to inhibit IL-1 production and pyroptosis, both in Hela 
cells and HaCaT keratinocytes (Song et al., 2020). 
 
1.4. IFI16 in autoimmune/autoinflammatory diseases 
Several reports have indicated IFI16 in autoimmunity. Since the interferon system is 
considered as a key player in autoimmune and autoinflammatory disorders such as systemic lupus 
erythemathosus (SLE), systemic sclerosis (SSc), Sjögren’s syndrome (SjS), and rheumatoid 
arthritis (RA), inflammatory bowel disease (IBD), it is conceivable to hypothesize an involvement 
of the IFN-inducible PYHIN proteins in the etiopathogenesis of autoimmune and 
autoinflammatory diseases (Jiang et al., 2020).  
Aberrant IFI16 expression (i.e., overexpression or de novo expression), at both mRNA and 
protein level, has been reported in colonic biopsies of patients with Crohn’s disease (CD) and 
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ulcerative colitis (UC), collectively known as IBD, compared to healthy controls (Caneparo et al., 
2016; Vanhove et al., 2015). IFI16 in the intestinal lamina propria is normally expressed in 
endothelial and inflammatory cells, whereas in IBD patients the colonic expression of IFI16 is 
substantially higher and well evident also in the epithelial cells.  
Another disease in which aberrant IFI16 expression has been observed is systemic lupus 
erythematosus (Costa et al., 2011; Mondini et al., 2007). Indeed, IFI16 distribution pattern in the 
skin was substantially different in SLE patients compared to healthy donors. IFI16 expression in 
normal skin was restricted to the nuclei, with evident positive staining in the keratinocytes. 
Conversely, in SLE biopsies, IFI16 staining in keratinocytes was stronger and intense positive 
nuclei were also found in the upper epidermal layers, indicating a keratinocyte specific 
cytoplasmic translocation of IFI16 in pathological setting.  
Finally, substantial evidence indicate that abnormal IFI16 expression can also be detected in 
the skin of patients affected by SSc (Mondini et al., 2006), or psoriasis (Cao et al., 2016; Chiliveru 
et al., 2014; Tervaniemi et al., 2016), as well as in salivary epithelial cells and infiltrating 
lymphocytes of individuals with SjS (Alunno et al., 2015; Antiochos et al., 2018).  
All these data clearly indicate a possible role of IFI16 in autoimmune/autoinflammatory 
disease. Importantly, several groups have reported a IFI16 mislocalization from nucleus to 
cytoplasm and an eventual release under viral infection, stress stimuli or pathological conditions 
(Antiochos et al., 2018; Bawadekar et al., 2015a; Orvain et al., 2020). In particular, IFI16 has 
been shown to be released into the exosomes of Epstein-Barr virus (EBV) or KSHV infected cells 
(Ansari et al., 2013; Singh et al., 2013). Similarly, at the late phases of HCMV infection induces, 
IFI16 is hijacked and incorporated within newly assembled egressing virion particles and exits 
the host environment (Dell’Oste et al., 2014). In addition, IFI16 mislocalization and release has 
also been observed in experimental models of keratinocyte monolayers and human skin explants 
after ultraviolet-B (UVB) exposure (Costa et al., 2011). Finally, serum circulating IFI16 has also 
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been observed in various autoimmune diseases including SSc, RA, SLE, SjS, and psoriatic 
arthritis (PsA) (Alunno et al., 2015, 2016; De Andrea et al., 2020; Gugliesi et al., 2013). 
The extracellular exposition of a protein usually expressed only in the nuclei of the cells 
causes the generation of specific autoantibodies. Indeed, IFI16 autoantibodies have been detected 
in a variety of autoimmune/autoinflammatory diseases. In 1994 Seelig et al. first detected anti-
IFI16 antibodies in a serum positive for antinuclear antibodies (ANAs), anti-SSA/Ro, and anti-
SSB/La autoantibodies. By immunoblotting analysis on recombinant IFI16 expressed as MS2-
polymerase fusion protein, these investigators also reported the presence of anti-IFI16 antibodies 
in 29% of sera obtained from 374 SLE patients (Seelig et al., 1994). With a different technique, 
such as serological analysis of antigens by recombinant cDNA expression cloning (SEREX), 
Uchida et al. detected anti-IFI16 antibodies in 70% of patients suffering from both primary and 
secondary SjS (Uchida et al., 2005). Moreover, Mondini et al. identified anti-IFI16 antibodies in 
21% of SSc patients by solid-phase enzyme-linked immunosorbent assay (ELISA), with a 
recombinant purified His-tagged IFI16 protein as antigen, and confirmed by ELISA that anti-
IFI16 autoantibodies titers are significantly elevated in patients with SLE and SjS compared with 
controls (Mondini et al., 2006). By using the latter technique, anti-IFI16 autoantibodies have been 
then detected in IBD (Caneparo et al., 2016), SLE (Caneparo et al., 2013), SjS (Alunno et al., 
2015; Baer et al., 2016), RA (Alunno et al., 2016), and PsA (De Andrea et al., 2020) patients. 
Overall, these data point to a pathogenic role of IFI16 in autoimmune/autoinflammatory diseases 
providing the rationale to investigate IFI16 extracellular activity. 
 
1.5. The lipopolysaccharide and its recognition 
The lipopolysaccharide (LPS) is the major component of the outer membrane of Gram-
negative bacteria, and probably the best characterized pathogen-associated molecular pattern 
(PAMP). LPS consists of three genetically, biologically and chemically distinct domains (Miller 
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et al., 2005) (Fig 4): (1) the more or less acylated and phosphorylated lipid A anchored in the 
bacterial outer membrane, representing the most immunogenic portion, and also called endotoxin, 
(2) the core oligosaccharide linked by 3-deoxy-d-manno-oct-ulosonic acid (Kdo) with lipid A, 
and (3) the O-antigen, with the latter pointing to the aqueous environment. Lipopolysaccharides 
that comprise all three regions are called smooth (S)-form LPS, while LPS lacking the O-antigen 
are named rough (R)-form LPS. Over the last 30 years, several reports have contributed to 
mechanistically dissect how the host system recognizes LPS. What is now known is that the 
recognition of LPS is a multistep process involving different proteins that convey the LPS 
molecule, through its lipid A moiety, to its receptor named Toll-like receptor 4 (TLR4) (Ryu et 
al., 2017). The first identified player of this process was the lipopolysaccharide-binding protein 
(LBP), a molecule able to opsonize LPS-bearing particles and intact Gram-negative bacteria, 
mediating attachment of coated particles to macrophages, which then secrete tumor necrosis 
factor α (TNFα) (Schumann et al., 1990; Tobias et al., 1986). The extracellular LBP forms direct 
contacts with the bacterial outer membrane (or micelles of LPS) and alters the outer membrane 
thereby facilitating the extraction of a single molecule of LPS by the protein CD14 (Gioannini et 
al., 2004). CD14 can either exist as a soluble extracellular protein or a 
glycosylphosphatidylinositol (GPI)-anchored protein embedded in the outer layer of the cell 
plasma membrane (Frey et al., 1992; Lee et al., 1993; Tobias et al., 1986; Wright et al., 1990). 
Regardless of its soluble or membrane-bound positioning, CD14 acts to transfer a single molecule 
of LPS to the protein MD2 (Gioannini et al., 2004). MD2 is a small protein that stably interacts 
with the ectodomain of TLR4, forming TLR4/MD2 heterodimers that represent the functional 
LPS receptor (Nagai et al., 2002; Shimazu et al., 1999). Indeed, the real LPS-binding site resides 
into MD2 giving to this molecule a critical role for LPS-mediated TLR4 activation. Upon CD14-
mediated transfer of LPS to MD2, TLR4-TLR4 dimerization occurs (Akashi et al., 2000). The 
lipid A moiety is the LPS portion that directly interacts with distinct regions of two TLR4/MD2 
heterodimers. The general structure of most of bacteria lipid A resemble that of Escherichia coli 
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lipid A, which is a diglucosamine diphosphate headgroup and six acyl chains. An elegant study 
by Park et al. revealed the structural basis for lipid A recognition by the TLR4/MD2 receptor 
(Park et al., 2009). The structure showed LPS binding to two copies of TLR4 and MD2 arranged 
symmetrically. Five of the six acyl chains present in hexacylated lipid A are buried in the 
hydrophobic pocket present in the MD2 component of a TLR4-MD2 heterodimer. In order to the 
dimerization to occur, the sixth acyl chain does not interact with the TLR4 component of this 
heterodimer, but rather interacts with a different TLR4 molecule. Moreover, the binding of LPS 
causes structural changes in MD2, leading to hydrophilic interactions between MD2 and TLR4, 
further stabilizing the complex. Finally, the two phosphate groups of lipid A, also play an 
important role in dimerization by binding to a positively charged cluster of lysines and an 
arginines on both TLR4 molecules. Therefore, lipid A structures that contain less than six acyl 
chains, or less than two phosphate groups, have minimal ability to crosslink distinct sets of 
TLR4/MD2 heterodimers, thus explaining their weakened inflammatory activities. This aspect 
will be discussed in detail later.  
 
Fig 4. LPS structure. LPS is composed of lipid A (endotoxin), core oligosaccharide and O-antigen (Miller et al., 2005). 
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Upon TLR4-TLR4 dimerization, several intracellular pathways are activated, ultimately 
leading to inflammation (Fig 5, and Kieser and Kagan, 2017). TLR4 has a cytosolic Toll/IL-1R 
(TIR) domain that after the dimerization are detected by the protein TIR domain containing 
adaptor protein (TIRAP) (Horng et al., 2001), which is a phosphoinositide-binding protein, 
subsequently leading to the assembly of a supramolecular organizing center named myddosome 
(Kagan et al., 2014). The myddosome consist of TIRAP, the adaptor molecule MyD88 (from that 
the name myddosome), and several IRAK family kinases that initiate downstream signaling that 
ultimately results in the activation of the transcription factors nuclear factor-kB (NF-kB) and 
activator protein1 (AP-1). 
 
Figure 5. LPS-induced pathways leading to inflammation. LPS is delivered in a LBP-CD14-dependent manner to the 
TLR4-MD2 receptor, prompting the dimerization and activation of TLR4, a process that leads to myddosome assembly 
(1). CD14 then promote the endocytosis of the dimerized TLR4 to promote triffosome assembly (2). Both pathways result 
in inflammation. LPS can reach the cytoplasm where can be sensed by caspase 11 (or caspase 4/5 in humans) leading to 
the non-canonical inflammasome activation, which in turn promotes pyroptosis and IL-1β release (3). Adapted from 
Kieser and Kagan, 2017. 
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Concomitantly, CD14 mediates the LPS-TLR4/MD2 internalization from the plasma 
membranes into endosomes (Zanoni et al., 2011). This process is independent of TLR4-TIR 
domains, but it is strictly dependent on CD14 and MD2 (Tan et al., 2015), even if CD14 can also 
promotes an LPS endocytosis without TLR4 (Dunzendorfer et al., 2004). When TLR4 is located 
in the endosome, there is the assembly of the so called triffosome with the adaptor molecules 
translocating chain-associated membrane protein (TRAM) and TIR-domain-containing adapter-
inducing interferon-β (TRIF) which are thought to only engage endosome-localized TLR4 
(Yamamoto et al., 2003). The formation of this complex ultimately leads to a second wave of NF-
kB and AP-1 activation and most importantly to the activation of the transcription factor IRF3 
which acts along with NF-kB and AP-1 to drive the expression of type I interferon (IFN) genes. 
Lastly, there is a recently discovered way in which LPS can be sensed directly into the 
cytoplasm of the host cell, independently of CD14-TLR4-MD2. LPS delivery into the cytoplasm 
induces a potent pyroptotic cell death response thanks to the activation of a non-canonical 
inflammasome (Hagar et al., 2013; Kayagaki et al., 2011, 2013). This response is important to 
prevent mammalian cells from being used as a growth substrate by intracellular bacteria 
(Jorgensen et al., 2017). LPS-induced pyroptosis is mediated by the cytosolic LPS receptor 
caspase-11 (or caspase-4 and caspase-5 in humans, Shi et al., 2014). LPS binding to the N-
terminal caspase activation and recruitment domain (CARD) of caspase-11, that can be mediated 
by the interferon-induced guanylate-binding proteins (GBPs, Santos et al., 2020), promotes the 
oligomerization of this protein, and the activation of its intrinsic protease activity. Active caspase-
11 then cleaves its cytosolic substrate gasdermin D (Kayagaki et al., 2015; Shi et al., 2015), 
releasing its N-terminal domain to oligomerize into a ring-shaped pore that disrupts the osmotic 
balance in the cell and ultimately causes swelling and disruption of the plasma membrane. 
Activated caspase-11 subsequently promotes NLRP3 activation dependent on potassium efflux 
(Rühl and Broz, 2015), probably because of GSDMD-mediated membrane perturbation, a known 
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activator of the NLRP3 inflammasome (Broz and Dixit, 2016), which ultimately leads to the 
processing and release of pro-IL1β and pro-IL18. 
Already in the early ‘80s it was observed that several natural and synthetic partial lipid A 
structures lacking one or both of the phosphate residues, or having less than six acyl chains  
display reduced or even no stimulatory activities in endotoxin-responsive human cells (Alexander 
and Rietschel, 2001). It know known that this reduced capacity its due to a reduced interaction 
with the TLR4/MD2, or with the CD14 (Tan et al., 2015), or to a reduced capacity to induce 
TLR4-TLR4 dimerization (Park et al., 2009). Indeed, this is a common strategy evolved by 
bacteria (both pathogenic and commensal) to not be sensed by the host organism (d’Hennezel et 
al., 2017; Tan and Kagan, 2014). Yersinia pestis, Francisella tularensis, and Shigella flexneri, 
provide examples of how bacteria can modify their lipid A structures. Y. pestis, the bacterium 
causing plague, exhibits different lipid A depending on the temperature. Indeed, Y. pestis mainly 
produces hexa-acylated lipid A at 25°C, whereas it synthesizes tetra-acylated lipid A at 37°C (i.e., 
human body temperature), thus facilitating immune evasion by this bacterium (Kawahara et al., 
2002). F. tularensis, the etiological agent of tularemia, is capable of synthesizing mono-
phosphorylated and tetra-acylated lipid A (Vinogradov et al., 2002). Finally, S. flexneri can 
remodel its lipid A structure specifically during its intracellular growth phase (Paciello et al., 
2013). Indeed, the majority of S. flexneri LPS purified from infected epithelial cells contained tri-
or tetra-acylated lipid A. Conversely, bacteria grown in broth produced hexa-acylated lipid A. 
Therefore, S. flexneri LPS triggers significantly lower amount of cytokine production via the 
TLR4 signaling pathway and dampens inflammasome activation in macrophages, as indicated by 
the reduced release of IL-1β. An interesting example is that of the LPS from Rhodobacter 
sphaeroides. Its lipid A is penta-acylated and can antagonize E. coli LPS binding to the 
TLR4/MD2 (Anwar et al., 2015). This is due because R. sphaeroides lipid A fully accommodate 
into the MD2 binding pocket, thereby preventing other LPS to bind, but lacking the sixth acyl 
chain it cannot induce TLR4-TLR4 dimerization, thereby not activating TLR4 signaling pathway.  
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1.6. Damage-associated molecular patterns 
One of the fundamental properties of the immune system is to initiate immune responses 
against invasive pathogens, based on the discrimination of “self” from “non-self”. However, 
innate immune response can also be activated without any infection. Therefore, in 1994 Polly 
Matzinger proposed the so called “danger theory” postulating that danger signals released by 
stressed or damaged cells can initiate immune responses (Matzinger, 1994). This theory led to the 
discovery of a number of endogenous molecules that are released during tissue damage, that were 
named damage-associated molecular patterns (DAMPs) (Land, 2003). It is now known that 
DAMPs are endogenous molecules that are normally sequestered intracellularly and are therefore 
hidden from recognition by the immune system under normal physiological conditions. However, 
under conditions of cellular stress or injury, these molecules can then be released into the 
extracellular environment by dying cells and trigger sterile inflammation (Chen and Nuñez, 
2010). Prototypical intracellular DAMPs are the chromatin-associated protein high-mobility 
group box 1 (HMGB1, Scaffidi et al., 2002), heat shock proteins (HSPs, Quintana and Cohen, 
2005), Ca2+-binding S100 proteins (Xia et al., 2018), nicotinate phosphoribosyltransferase 
(NAPRT, Managò et al., 2019), oxidized phospholipids (oxPAPC, Zanoni et al., 2017), and purine 
metabolites, such as ATP (Bours et al., 2006) and uric acid (Kono et al., 2010). In addition, there 
are also extracellularly located DAMPs. These are typically released by extracellular matrix 
degradation during tissue injury and include hyaluronan (Frey et al., 2013), heparan sulphate 
(Brennan et al., 2012), biglycan (Schaefer et al., 2005), fibronectin-EDA (Malara et al., 2019), 
and tenascin-C (Midwood et al., 2009). 
Over the past 20 years, numerous new DAMP-receptor axes have been discovered in various 
injury scenarios, with both PRR and non-PRR playing a key role in DAMP-mediated innate 
immunity activation (Gong et al., 2020). Nucleic acids released from damaged cells can activate 
TLR3, TLR7 and TLR9, and intracellular proteins released by damaged cells and extracellular 
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matrix components cleaved following tissue injury can activate TLR2 and TLR4. Of particular 
interest is the TLR4, as it can be bound and activated from the majority of DAMPs. Indeed, many 
therapeutic strategies are ongoing in order to block TLR4 activation in several diseases (Garcia 
et al., 2020; Romerio and Peri, 2020). Tenascin-C, an extracellular matrix glycoprotein associated 
with tissue injury and repair, was shown to induce pro-inflammatory cytokines synthesis in 
macrophages, through its fibrinogen-like globe (FBG). This activity was mediated by the binding 
and the activation of the TLR4, in a MyD88-dependent manner, as neutralizing antibodies to 
TLR4, genetic deletion of TLR4 or expression of a dominant negative MyD88 mutant completely 
abrogates Tenascin-C proinflammatory activity (Midwood et al., 2009). Subsequential analyses 
have also identified tenascin-C specific sites that directly and cooperatively interact with TLR4 
(Zuliani-Alvarez et al., 2017). HMGB1, maybe the most studied DAMP, has been shown to bind 
and activate TLR4/MD2 to produce proinflammatory cytokines (Yang et al., 2010, 2015a). 
Interestingly, HMGB1 proinflammatory activity was also confirmed using necrotic wild-type 
(WT) or HMGB1-knockout (HMGB1-KO) cells, proving that TLR4 activation was not due to 
bacterial contaminants in the recombinant protein. Surface plasmon resonance (SPR) analysis has 
revealed that HMGB1-TLR4-MD2 interaction is initiated by HMGB1-TLR4 binding via HMGB-
1 A-box domain (high affinity and slow off-rate) and, once in close proximity, the HMGB1 B-
box domain binds to MD2 (low affinity but extremely slow off-rate) (He et al., 2018). However, 
HMGB-1 is a pleiotropic DAMP since it can also bind and activate different receptors, such as 
TLR2 or receptor for advanced glycation endproducts (RAGE, Yang et al., 2015b). The latter, in 
particular, is a non-PRR demonstrating that, differently from PAMPs, DAMPs can be recognized 
by a variety of receptors to induce inflammation, promoting the idea that continue exposition of 
these molecules to the extracellular environment can lead to unresolve chronic inflammation. The 
reason why DAMPs can activate the innate immune response is that, after an injury, they are key 
players in promoting tissue repair and regeneration (Pandolfi et al., 2016; Vénéreau et al., 2015). 
However, unresolved chronic inflammation is detrimental to the host and can lead to sterile 
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inflammatory diseases, including metabolic disorders, neurodegenerative diseases, autoimmune 
diseases and cancer (Roh and Sohn, 2018). Accordingly, high levels of DAMPs occur locally 
and/or systemically in many of these conditions. For example, a wide range of endogenous TLR 
activators, including heat shock proteins, HMGB1, and tenascin-C, has been observed in synovia 
of RA patients but not in synovia from normal joints or non-inflamed synovia from osteoarthritis 
(OA) patients (Baillet et al., 2010; Goldstein et al., 2007; Midwood et al., 2009). Tenascin-C 
levels are also elevated in SSc skin biopsy samples and serum, and in fibrotic skin tissues from 
mice (Bhattacharyya et al., 2016, 2018). Indeed, tenascin-C stimulates collagen gene expression 
and myofibroblast transformation via TLR4 signaling. High levels of HMGB1, NAPRT, and 
tenascin-C circulate in the serum of septic patients (Schenk et al., 1995; Wang et al., 1999), and 
high serum concentrations of DNA-containing immune complexes are associated with SLE (Tian 
et al., 2007). In many cases levels of endogenous TLR activators are indicative of disease activity; 
elevated levels of extracellular HMGB1 localize specifically to active lesions of multiple sclerosis 
(MS) patients and correlate with active inflammation (Andersson et al., 2008). Further support of 
a role for endogenous TLR activators in driving disease has also been derived from in vivo studies 
using experimental models of inflammatory disease, where not high levels of serum DAMPs were 
found, but also the administration of exogenous DAMPs were sufficient to initiate inflammation. 
As an example intra-articular injection of the TLR4 activators fibronectin-EDA or tenascin-C has 
been shown to induce joint inflammation in wild type but not in TLR4 null mice (Gondokaryono 
et al., 2007; Midwood et al., 2009). Interestingly, inhibition of DAMP function through 
neutralizing antibodies, small molecules and genetic deletion can ameliorate disease in vivo, 
further supporting a key role of DAMP in driving persistent inflammation and point to their 





1.7. DAMPs and PAMPs interaction: HMGB-1 as an example 
As PAMPs and DAMPs can be recognized by the same receptors, it is conceivable that both 
molecules can synergize to amplify and sustain proinflammatory response. Indeed, it is known 
that DAMPs extracellular released can be promoted by PAMPs such as LPS, viruses, fungi by 
promoting cellular damage. In addition, these molecules can physically associate to result in a 
more prominent innate immune activation. In 2008, HMGB-1 was found to facilitate the transfer 
of LPS to CD14 thereby enhancing its proinflammatory activity (Youn et al., 2008). By means of 
a series of enzyme-linked immunosorbent assays (ELISAs) and SPR experiments, the authors 
showed that a physical interaction occurs between HMGB1 and LPS. Interestingly, this 
interaction was responsible for a significant enhancement of the LPS-mediate immune activation. 
Accordingly, the blockade of HMGB-1-LPS interaction through the use of synthetic peptides, 
completely abrogated HMGB-1-LPS synergism (Youn et al., 2011). Moreover, it was also shown 
that HMGB-1 synergizes with both endogenous and exogenous molecules, such as the synthetic 
derivate of triacylated bacterial lipoproteins Pam3CSK4, or the microbial CpG-DNA, in inducing 
a strong immune response. Finally, in 2018 Deng et al. demonstrated that hepatocyte-released 
HMGB1 binds to LPS and targets its internalization into the lysosomes of macrophages and 
endothelial cells via RAGE. Subsequently, HMGB1 permeabilizes the phospholipid bilayer in the 
acidic environment of lysosomes, resulting in LPS leakage into the cytosol and caspase-11 
activation and cell death for pyroptosis (Deng et al., 2018). Altogether, these results suggest that 
PAMPs and DAMPs orchestrate innate immune activation, providing the rationale to investigate 






2. Aim of the study 
Briefly, the autoinflammatory/autoimmune activity of IFI16 can be summarized through the 
following steps: 1) IFI16 expression is enhanced in damaged tissues of patients affected by 
autoimmune/autoinflammatory diseases as a result of abnormal type I IFN production and/or other 
proinflammatory stimuli, including UVB; 2) IFI16 is then released as a consequence of increased cell 
damage/stress; 3) the released IFI16 protein leads to a breakdown in tolerance to self-antigens; 4) this 
loss of tolerance favors the generation of specific anti-IFI16 autoantibodies; 5) IFI16 freely 
circulating may act as a DAMP, amplifying the injury of target cells. 
In an attempt to investigate IFI16 extracellular activity, Gugliesi et al. treated HUVEC with 
different concentrations of recombinant IFI16 (Gugliesi et al., 2013). By using several techniques, 
they demonstrated that extracellular IFI16 did not affect HUVEC cell viability, but severely limits 
their tubulogenesis and transwell migration activities, through a direct binding on HUVEC plasma 
membranes. Interestingly, these inhibitory effects were fully reversed in the presence of anti-IFI16 
N-terminal antibodies, suggesting that its extracellular activity resides within its N-terminal domain. 
These results were further corroborated by Bawadekar et al., who expanded on HUVEC treatment 
with extracellular IFI16 demonstrating that recombinant IFI16 caused dose/time-dependent mRNA 
upregulation of pro-inflammatory cytokines such as IL-6, IL-8, CCL2, CCL5, CCL20, ICAM1, and 
VCAM1 (Bawadekar et al., 2015b). Interestingly, the IFI16-mediated release of IL-6 and IL-8 was 
enhanced when a combinatorial IFI16-LPS treatment was performed.  
Altogether, these results clearly pointed out to a role of extracellular IFI16 as a DAMP. Moreover, 
they suggested an interaction between IFI16 and LPS. 
Therefore, this PhD project aimed to: 
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1) Mechanistically dissect the interaction between LPS and IFI16, using not only the canonical 
TLR4-activator LPS (e.g., LPS form E. coli), but also TLR4-weak activator or TLR4-
antagonist LPS (e.g., LPS from P. gingivalis, and LPS from R. sphaeroides); 
2) Corroborate the role of IFI16 as a novel DAMP using other target cells, and explore the 
biological impact of the IFI16-LPS complex; 
3) Characterize the membrane-bound receptor responsible for IFI16 (-LPS)-mediated pro-
inflammatory activity; 

















3. Materials and methods 
3.1. Reagents, antibodies, and recombinant proteins 
LPS from Escherichia coli O111:B4 (LPS-EB), Porphyromonas gingivalis (LPS-PG) or 
Rhodobacter sphaeroides (LPS-RS), biotin-labeled LPS from Escherichia coli O111:B4 (biotin-
labeled LPS-EB), detoxified LPS from Escherichia coli O111:B4 (detoxLPS) and polimixin B 
(PMB) were all purchased from InvivoGen. LPS from Escherichia coli F583 (LPS-F583), 
monophosphoryl lipid A from Escherichia coli F583 (MPLA), diphosphoryl lipid A from 
Escherichia coli F583 (DPLA) were purchased from Sigma-Aldrich. Bovine serum albumin 
Fraction V pH 7 (BSA) was purchased from Euroclone.  
The following antibodies were used: mAb anti-human TLR4 (sc-293072, Santa Cruz 
Biotechnologies), mAb anti-human TLR4 (sc-13593, Santa Cruz Biotechnologies), mAb anti-
human TLR4 (mabg-htlr4, InvivoGen), rabbit polyclonal anti-MD2 (AHP1717T, Bio-Rad), 
rabbit monoclonal anti-MyD88 (4283, Cell Signaling Technology), mAb anti-NF-κB p65 (sc-
8008 X, Santa Cruz Biotechnologies), PE mouse anti-human CD14 (555398, BD Pharmingen), 
mAb anti-β-actin (A1978, Sigma-Aldrich), rabbit IgG-HRP (A6154, Sigma-Aldrich,), mouse 
IgG-HRP (NA931V, GE Healthcare), streptavidin-HRP (E2886, Sigma-Aldrich,), mouse IgG-
Alexa Flour 488 (A11001, Thermo Fisher Scientific), normal mouse IgG2a isotype control (sc-
3878, Santa Cruz Biotechnologies). Rabbit polyclonal anti-IFI16 N-term and C-term were 
produced as described previously (Gariglio et al., 2002). Briefly, N-terminus or C-terminus IFI16 
cDNA from pBKS-IFI16 (kindly provided by J. Trapani, The Peter MacCallum Cancer Institute, 
Victoria, Australia) were cloned into a pGEX-4T-2 vector (Pharmacia, Uppsala, Sweden) to 
create an in-frame fusion protein with the GST coding region. The expression of N-terminus or 
C-terminus GST-IFI16 fusion protein in the Escherichia coli host AD202 was induced by 
treatment with 0.1 mM isopropyl-b-D-thiogalactopyranoside (IPTG) for 3 h. The bacterial cells 
were harvested by centrifugation, resuspended in cold lysis buffer (0.5 mg/ml lysozyme, 25 mM 
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Tris-HCl, pH 7.9, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 10% glycerol, 0.2% Triton X-100 
containing 2 mM PMSF, 50 mM pepstatin A, and 50 mM leupeptin as protease inhibitors) and 
lysed by sonication. Fusion proteins were purified from the cleared lysate by glutathione-
Sepharose affinity chromatography. Antisera against IFI16 were raised by injecting rabbits with 
the purified GST-IFI16 fusion proteins. The sera obtained after bleeding at 1 week after the fourth 
immunization were precipitated with ammonium sulfate at 45% saturation. The precipitate was 
then resuspended in phosphate-buffered saline (PBS) and purified on a protein A affinity column 
(Pharmacia) according to the specification of the supplier. 
Human recombinant IFI16, IFI16 domains (i.e., PYRIN, HINA and HINB), and IFI16 variants 
lacking the HINB domain (i.e., IFI16ΔHINB) or the PYRIN domain (i.e., IFI16ΔPYRIN) were 
produced as previously described (Bawadekar et al., 2015b). Briefly, the different coding regions 
were amplified from the full-length human IFI16 cDNA (isoform b) and cloned in a pET30a 
expression vector (Novagen) containing an N-terminal histidine tag. The expression of the 
proteins in the ClearColi® BL21(DE3) host (to ensure no endotoxin contamination) and the lysis 
of the bacteria, were performed as described above. Recombinant proteins were purified from the 
cleared lysate by nickel-affinity purification and stored at - 80°C in endotoxin-free vials. 
GST recombinant protein was expressed using pGEX-4T2 vector and purified according to 
standard procedures. The purity of the proteins was assessed by 12% SDS-polyacrylamide gel 
electrophoresis. Recombinant TLR4 protein and TLR4/MD2 complex (478-TR-050 and 3146-
TM-050/CF, respectively) were purchased from R&D Systems. 
 
3.2. Pull-down assay, ELISA and competitive ELISA 
Biotin-labeled LPS-EB (10 µg) was incubated with 30 µl of streptavidin sepharose high 
performance beads (GE Healthcare) for 3 h at 4°C. After a washing step, 3 µg of recombinant 
IFI16, PYRIN, HINA, HINB, IFI16ΔHINB, or GST were added and incubated O/N at 4°C. After 
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five washes with 1X PBS with 0.25% Triton X-100 (Sigma-Aldrich), samples were boiled in 
sample buffer containing SDS and β-mercaptoethanol and centrifuged. Supernatants were 
separated on a 7.5% or 12% SDS-polyacrylamide gel (Bio-Rad). Gels were stained with 
Coomassie brilliant blue (Serva Electrophoresis GmbH) for protein visualization. 
For saturation binding experiments, microtiter plates (Nunc-Immuno MaxiSorp, Thermo 
Fischer Scientific) were coated with 2 µg/ml of recombinant IFI16 or 10 µg/ml of BSA or GST 
in 1X PBS O/N at 4°C. After a washing step with 1X PBS and 0.25% Tween 20 (v/v, Sigma-
Aldrich) and blocking step with 1X PBS with 3% BSA and 0.05% Tween 20 for 1 h, increasing 
concentrations of biotin-labeled LPS-EB, preincubated with 10 µg/ml of polymyxin B (PMB) 
when specified, were added to the wells and incubated for 1 h at room temperature (RT). Bound 
proteins were then detected using HRP-conjugated streptavidin. TMB solution (Thermo Fischer 
Scientific) was used for color development, and OD was measured at 450 nm. Alternatively, 
microtiter plates were coated with 10 µg/ml of LPS-EB, LPS-PG, LPS-RS, LPS-F583, MPLA, 
DPLA, or detoxLPS in 1X PBS for 24 h at RT. After washing and blocking for 2 h, increasing 
concentrations of IFI16, PYRIN, HINA, or HINB were added to the wells, preincubated with 10 
µg/ml of PMB when specified, for 2 h. Anti-IFI16 antibodies against the N- or the C-terminus of 
the protein and HRP-labeled anti-rabbit IgG were then added as primary and secondary 
antibodies, respectively. The binding was detected as described above.  
For whole-cell ELISA, different strains of bacteria (i.e., gram-positive: Staphylococcus 
aureus, Staphylococcus epidermidis and Streptococcus pyogenes; gram-negative: Escherichia 
coli and Klebsiella pneumonia) were grown in LB medium without antibiotics and, after washing 
with 1X PBS, fixed in 0.5% formalin O/N at 4°C. Subsequently, the bacteria were diluted to an 
OD600 of 0.5 and were used to coat microtiter plates O/N at 37°C. After blocking, increasing 
concentrations of IFI16 were added to the wells and incubated for 2 h at RT. Anti-IFI16 antibodies 
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against the N-terminus of the protein and HRP-labelled anti-rabbit IgG were then added as 
primary and secondary antibody, respectively, and binding was detected as described above.  
For competitive ELISA, microtiter plates were coated with 1 µg/ml LPS-EB in 1X PBS O/N 
at RT. Successively, a constant amount of 2 µg/ml IFI16 was added to the wells in the presence 
of increasing concentration of LPS-EB, MPLA or detoxLPS. After incubation for 4 h at RT under 
gentle agitation, plates were incubated with an anti-IFI16 N-terminal primary antibody and an 
HRP-conjugated anti-rabbit IgG secondary antibody. The binding was detected as described 
above. To determine KD constants, saturation binding experiments were performed, and data 
were fitted to the Langmuir isotherm equation, which describes the equilibrium binding of the 
ligands (Hulme and Trevethick, 2010). Data are reported as sigmoid concentration-response 
curves plotted against log concentrations. 
 
3.3. Cell cultures, treatments and transfection 
Human kidney adenocarcinoma cells 786-O, human leukemia monocytes THP-1, and mouse 
macrophages RAW 264.7 were obtained from ATCC and grown in RPMI 1640 Medium (Sigma-
Aldrich) containing 10% of fetal bovine serum (FBS, Immunological Sciences) and 1% of 
penicillin/streptomycin/glutamine solution (PSG, Gibco) at 37°C and 5% CO2. Wild-type and 
IFI16-knockout (U2OS-IFI16-/-) human osteosarcoma cells U2OS were kindly gifted by Dr. Bala 
Chandran (University of South Florida, FL, USA; (Cigno et al., 2015) and grown in Dulbecco’s 
modified Eagle’s medium (Sigma-Aldrich) containing 10% of FBS and 1% of PSG at 37°C and 
5% CO2. UVB irradiations were performed as previously described (Costa et al., 2011). Briefly, 
UV irradiation were performed in PBS and provided by a UVB lamp (HD 9021; Delta Ohm S.r.l., 
Padova, Italy), which emits most energy within the UVB range (280–315 nm), with an emission 
peak at 312 nm. Irradiation intensity was monitored by a UVB irradiance meter cosine corrector 
with spectral range of 280–319 nm (LP 9021 RAD; Delta Ohm). Following irradiation with the 
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required UVB dose, cells were incubated in complete medium for 16h at 37 °C in a humidified 
5% CO2 atmosphere. The resulting cell culture supernatants were centrifuged to remove any 
cellular pellet and stored at -80°C for the following experiments.  
For treatments, cells were stimulated in complete medium with IFI16, PYRIN, HINA, HINB, 
IFI16ΔHINB, IFI16ΔPYRIN, MPLA, DPLA, LPS-F583, LPS-EB, LPS-RS, alone or pre-
complexed by O/N incubation at 4°C, unless specified otherwise. Additionally, cells were 
stimulated with supernatants of untreated or UVB-treated U2OS or U2OS-IFI16-/- cells alone or 
preincubated O/N at 4°C with LPS-EB, or LPS-RS. LPS variants or lipid A moieties were used 
at a concentration of 10 ng/ml. All treatments were carried out at 37°C and 5% CO2. 
For TLR4 neutralization, THP-1 cells were pretreated with 10 μg/ml of anti-TLR4 antibodies 
for 1 h before treatments. For treatments with anti-IFI16 antibodies, IFI16 was incubated with 
rabbit polyclonal anti-IFI16 N-term or C-term for 1 h at RT before treatments. 
For TLR4, MD2 or Myd88 gene silencing, cells were transfected with specific human TLR4, 
MD2, Myd88 or control siRNAs (Dharmacon, siGENOME smart pool) using DharmaFect1 
transfection reagent (Dharmacon). The efficiency of knockdown was confirmed by FACS 
analysis and immunoblotting at 48 h after transfection.  
 
3.4. FACS analysis 
Single cell suspensions were incubated for 30 min on ice with anti-TLR4 (sc-13593), PE-
conjugated anti-CD14 (555398) or with isotype control diluted in staining buffer (PBS 1% FBS 
0.1% NaN3). To detect TLR4 staining, cells were further washed and incubated for 30 min on ice 
with Alexa Fluor 488-conjugated secondary antibody. Cell counts and fluorescence intensity 
measurements were calculated by Attune NxT Flow Cytometer (Thermo Fisher Scientific). 
Background fluorescence was subtracted using unlabeled cells, and channel compensation was 
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performed using Attune performance tracking beads (Thermo Fisher Scientific). A total of 10,000 
events were recorded. Data were analyzed by FlowJo cell analysis software (BD Life Sciences). 
 
3.5. Western blot and immunoprecipitation 
Whole-cell extracts were prepared using RIPA lysis and extraction buffer (Pierce) with halt 
protease and phosphatase inhibitor (Thermo Fisher Scientific) on ice, and total protein 
concentration was quantified by Bradford Reagent (Sigma-Aldrich) measuring absorbance at 595 
nm. Twenty µg of cell extracts, or 30 μl of U2OS culture supernatants were separated by 
electrophoresis on 7.5% or 12% SDS-polyacrylamide gels (Bio-Rad), transferred to nitrocellulose 
membranes, blocked with 10% non-fat milk in tris-buffered saline-tween (TBST), and probed 
with specific primary antibodies O/N at 4°C. After being washed with TBST, membranes were 
incubated with specific HRP-conjugated secondary antibodies, and binding was detected by ECL 
(Thermo Fisher Scientific, Super Signal West Pico). Expression of β-actin was used as protein 
loading control.  
Co-immunoprecipitation of TLR4 with interacting proteins was performed using the 
Dynabeads Protein G Immunoprecipitation Kit (ThermoFisher), according to the manufacturer’s 
instructions with minor modifications. Briefly, after lysis of treated cells, 20 µg of total cell 
extracts were kept as the input control, while 90 µg of total cell extracts were incubated for 1 h at 
RT with 2.5 µg of anti-TLR4 antibody previously conjugated with magnetic beads. The resulting 
complexes were then washed, eluted, denatured, and subjected to Western blotting as described 
above. For DNase-treated cell extracts, DNase I (Sigma Aldrich) was added at a 1:10 dilution and 
incubated for 15 min at RT. Images were acquired, and densitometry of the bands was performed 
using Quantity One software (version 4.6.9, Bio-Rad). Densitometry values were normalized 




3.6. Quantitative real time PCR 
Quantitative real-time PCR (qRT-PCR) was performed on a CFX96 Real-Time PCR 
Detection System (Bio-Rad) as previously described (Albertini et al., 2018). Briefly, total RNA 
was extracted using TRI Reagent (Sigma-Aldrich), and 1 g was retrotranscribed using an iScript 
cDNA Synthesis Kit (Bio-Rad). Reverse-transcribed cDNAs were amplified in duplicate using 
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad), up to 40 cycles of PCR. The human 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene, or the murine actin gene, were used 
as housekeeping gene to normalize for variations in cDNA levels. The relative normalized 
expression after stimulation as compared to control was calculated as fold change = 2 -Δ(ΔCT) where 
ΔCT = CTtarget - CTGADPH and Δ(ΔCT) = ΔCTstimulated - ΔCTcontrol. Primer sequences are 
summarized in Table 1.  
 
Table 1. List of primers used for qRT-PCR (h: human; m: mouse). 
Gene Forward (5’ to 3’) Reverse (5’ to 3’) 
   
hIL-6 ACCGGGAACGAAAGAGAAGC CTGGCAGTTCCAGGGCTAAG 
hIL-8 ATGACTTCCAAGCTGGCCGTGGCT TCTCAGCCCTCTTCAAAAACTTCTC 
hTNF-α GCCAGAGGGCTGATTAGAGA TCAGCCTCTTCTCCTTCCTG 
hIL-1β TCCCCAGCCCTTTTGTTGA TTAGAACCAAATGTGGCCGTG 
hGAPDH AACGTGTCAGTGGTGGACCTG AGTGGGTGTCGCTGTTGAAGT 
mACTIN CCCAAGGCCAACCGCGAGAAGAT GTCCCGGCCAGCCAGGTCCAG 
mIL-6 GGATACCACTCCCAACAGACCT GCCATTGCACAACTCTTTTCTC 






3.7. Cytokines measurement by ELISA 
Cytokines secreted in culture supernatants after treatments were analyzed using human IL-6 
DuoSet ELISA and human IL-8 DuoSet ELISA (all from R&D Systems), human TNF-α 
Uncoated ELISA and human IL-1β Uncoated ELISA (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. Absorbance was measured using a Spark multimode microplate 
reader (Tecan). 
 
3.8. Transcription factor assay 
Nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents 
(Thermo Fisher Scientific), according to the manufacturer’s instructions. NF-κB binding activity 
to a DNA probe containing its binding consensus sequence was measured by Universal 
Transcription Factor Assay Colorimetric kit (Merck Millipore). The binding of NF-κB to the 
DNA probe was revealed using a specific primary antibody, with an HRP-conjugated secondary 
antibody used for detection with TMB substrate. The intensity of the reaction was measured at 





3.9. Surface plasmon resonance analysis 
The Biacore X100 (GE Healthcare) instrument was used for real-time binding interaction 
experiments. Recombinant TLR4 or TLR4/MD2 complex was covalently immobilized onto the 
surface of sensor CM5 (cat # BR100012, GE Healthcare) chips via amine coupling. TLR4 was 
diluted to a concentration of 10 μg/ml in 10 mM sodium acetate at pH 4.0, while TLR4/MD2 
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complex was diluted to a concentration of 20 μg/ml in the same buffer. Both proteins were injected 
on CM5 chips at a flow rate of 10 μl/min, upon activation of the carboxyl groups on the sensor 
surface with 7-min injection of a mixture of 0.2 M EDC and 0.05 M NHS. The remaining esters 
were blocked with 7-min injection of ethanolamine. Taking into account the ligands (TLR4 or 
TLR4/MD2) and analytes (IFI16, LPS-EB or IFI16/LPS-EB) molecular weights (MW) of 70 or 
90 kDa, and 90, 10 or 100 kDa respectively, the appropriate ligand density (RL) on the chip was 
calculated according to the following equation: RL = (ligand MW/analyte MW) × Rmax × (1/Sm), 
where Rmax is the maximum binding signal and Sm corresponds to the binding stoichiometry. 
The target capture level of the TLR4 or TLR4/MD2 was of 596.0 or 1223.9 response units (RUs), 
respectively. The other flow cell was used as a reference and was immediately blocked after the 
activation. Increasing concentrations of endotoxin-free IFI16, LPS-EB or IFI16/LPS-EB complex 
were flowed over the CM5 sensor chip coated with TLR4 or TLR4/MD2 at a flow rate of 30 
μl/min at 25°C with an association time of 120 s for IFI16 alone and the IFI16/LPS-EB complex, 
and 180 s for LPS-EB, and a dissociation phase of 180 s for IFI16 and IFI16/LPS-EB complex or 
600 s for LPS-EB. A single regeneration step with 50 mM NaOH was performed following each 
analytic cycle. All the analytes tested were diluted in the HBS-EP+ buffer (GE Healthcare).  
Recombinant IFI16 was covalently immobilized onto the surface of sensor CM5 chips via 
amine coupling as done for TLR4 and TLR4/MD2 complex. IFI16 was diluted to a concentration 
of 25 µg/ml in 10 mM sodium acetate at pH 4.0. The target capture level of IFI16 was of 1926.6 
response units (RUs). Increasing concentrations of LPS-EB, diluted in HBS-EP+ buffer, were 
flowed over the CM5 sensor chip coated with IFI16 at a flow rate of 30 μl/min at 25°C with an 
association time of 180 s and a dissociation phase of 600 s. A single regeneration step with 50 
mM NaOH was performed following each analytic cycle. The KDs were evaluated using the 
BIAcore evaluation software (GE Healthcare) and the reliability of the kinetic constants 




For the binding inhibition experiments, a fixed concentration of IFI16 (500 nM) was incubated 
with increasing concentrations of rabbit polyclonal anti-IFI16 N-term or C-term for 1 h at RT, 
diluted in HBS-EP+ buffer. IFI16–antibody complexes were injected over the TLR4/MD2 sensor 
chip surface for 120 s and allowed to dissociate for 180s. A single regeneration step with 50 mM 
NaOH was performed following each analytic cycle. Data were background-subtracted using the 
adjacent control flow cell and buffer-alone injections. The reported RUs were calculated using 
the BIAcore evaluation software. 
 
3.10. Statistical analysis 
All statistical analyses were performed using GraphPad Prism version 6.00 for Windows 
(GraphPad Software, La Jolla California USA, www.graphpad.com). The data are expressed as 
mean ± SD. For comparisons between two groups, means were compared using a two-tailed 
Student’s t test. For comparisons among three groups, means were compared using one-way or 
two-way ANOVA followed by Dunnett’s test. Differences were considered statistically 












4.1. IFI16 binds to LPS of different bacterial origin and inflammatory activity   
To investigate the occurrence of a direct association between IFI16 and LPS, we performed 
an in vitro pull-down assay using biotin-labeled LPS from E. coli O111:B4 (biotin-LPS-EB) and 
human recombinant IFI16 protein. As shown in Fig 6A, we could readily detect a highly 
reproducible ~100-kDa band corresponding to biotin-LPS-bound IFI16. To rule out that this 
binding was due to bacterial contaminants, we next performed a pull-down assay using a 
recombinant glutathione-S transferase (GST) protein prepared with the same procedure as that 
employed to obtain recombinant IFI16. As shown in Fig 6B, we failed to isolate any GST-
containing band following incubation of GST with biotin-LPS-EB and streptavidin beads, 
demonstrating the specificity of the IFI16/LPS interaction.  Furthermore, saturation binding 
experiments using IFI16-coated microtiter plates challenged with increasing amounts of biotin-
LPS-EB revealed biotin-labeled LPS bound to solid-phase IFI16 in a concentration-dependent 
manner, reaching saturation at 100,000 ng/ml of biotin-LPS-EB (Fig 6C). When recombinant 
GST or BSA were coated onto the microtiter plates, no binding occurred in the presence of biotin-
LPS-EB (Fig 6C). To assess binding specificity, we asked whether polymyxin B (PMB), an LPS-
sequestering agent able to bind to negatively charged phosphate groups of lipid A (Velkov et al., 
2013), would disrupt IFI16/LPS interaction. As shown in Fig 6C, when PMB was pre-incubated 
with biotin-LPS-EB and then added to the IFI16-coated wells, it completely prevented IFI16 from 
binding to LPS. Next, IFI16/LPS-EB interaction was confirmed by surface plasmon resonance 
(SPR) analysis flowing increasing amounts of LPS-EB over a CM5 IFI16-coated chip. As shown 
in Fig 6D, LPS interacted with IFI16 in a concentration-dependent manner, with a kinetic 
association constant (Ka) of 1.13*10
4 1/Ms and a kinetic dissociation constant (Kd) of 1.94*10
-3 
1/s, respectively.  
39 
 
Altogether, these results indicate that IFI16 binds to LPS-EB with high affinity and that such 
interaction is inhibited by PMB, presumably by masking the negatively charged groups of the 
LPS lipid A moiety. 
We next sought to determine whether IFI16 could bind to LPS in its natural setting, such as 
the outer membrane of fixed gram-negative bacteria. To this end, a panel of gram-negative 
bacteria, including a laboratory strain of E. coli and a clinical isolate of Klebsiella pneumoniae, 
were assessed as solid phase antigens by whole cell ELISA. Gram-positive clinical isolates of 
Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus pyogenes were used as 
negative controls. As shown in Fig 6E, IFI16 strongly associated with the surface of both gram-
negative bacteria species. By contrast, no IFI16 binding could be detected when gram-positive 
bacteria were used as solid phase antigens (Fig 6E). Thus, IFI16-LPS binding can also occur in 
the natural setting where LPS is anchored to the bacterial outer membrane by its lipid A moiety. 
We next asked whether IFI16 would bind with the same affinity to LPS variants derived from 
different gram-negative strains with highly variable structure and broad-spectrum activity. For 
this purpose, microtiter plates were coated with the following LPS variants: 1) the two full TLR4 
agonists E. coli O111:B4 (LPS-EB) and E. coli F583 (LPS-F583), with the latter harboring a 
similar lipid A moiety but a shorter polysaccharide chain length compared to that of the O111:B4 
strain; 2) the weak TLR4 agonist P. gingivalis (LPS-PG), carrying a mixture of di-, mono- and 
de-phosphorylated penta- or tetra-acylated lipid A moieties; or 3) the TLR4 antagonist R. 
sphaeroides (LPS-RS), harboring a di-phosphorylated lipid A loaded with 3 long and 2 short acyl 
chains (Fig 6F). As shown in Fig 6G, IFI16 was able to bind to all the aforementioned solid-phase 
LPS variants in a concentration-dependent manner, although with slightly different kinetics. 
Specifically, we obtained similar KDs for the two E. coli LPS variants—i.e., 4.2 nM and 4.3 nM 
for LPS-EB and LPS-F583, respectively—, while we observed slightly higher KDs for LPS-PG 
and LPS-RS—i.e., 12.0 nM and 19.3 nM, respectively (Table 2). Consistently, treatment of 
immobilized LPS molecules with PMB prior to the addition of IFI16 completely abolished IFI16 
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binding. Thus, IFI16 binds to not only the canonical TLR4-activating LPS but also variants 
characterized by weaker triggering activity. 
 
 
Table 2. Full-length IFI16 and IFI16 domains binding affinities to LPS 
LPS variant Equilibrium dissociation constant (KD), nM 
 IFI16 PYRIN HINA HINB 
LPS E. coli O111:B4 (LPS-EB) 4.2 116.5 85.3 3.3 
LPS E. coli F583 (LPS-F583) 4.3 - - - 
LPS P. gingivalis (LPS-PG) 12.0 46.9 84.0 1.6 
LPS R. sphaeroides (LPS-RS) 19.3 - - - 
DPLA E. coli F583 (DPLA) 0.9 47.5 67.7 2.8 
MPLA E. coli F583 (MPLA) 1.2 47.2 94.1 2.7 
Detoxified LPS E. coli O111:B4 (detoxLPS) >  20 - - - 












Fig 6. IFI16 binds to LPS of different bacterial origin and inflammatory activity. Coomassie brilliant blue staining 
of pull-down assays performed with 3 g of recombinant IFI16 (A) or GST (B) in the presence or absence of biotin-
labeled lipopolysaccharide (LPS) from E. coli O111:B4 (biotin-LPS-EB). (C) Saturation binding experiments performed 
42 
 
with 2 g/ml of IFI16 (red circles) and increasing amount of biotin-LPS-EB. Binding was detected by ELISA using HRP-
conjugated streptavidin. Optical density (OD) of samples was measured at 450 nm. An excess of recombinant GST (blue 
circles) or BSA (green circles) and pre-treatment of biotin-LPS-EB with polymyxin B (PMB, empty circles) were used 
as negative controls. Data are expressed as mean values ± SD of three independent experiments. (D) Surface plasmon 
resonance (SPR) analysis of LPS-EB binding to immobilized IFI16. After immobilization of IFI16 on the CM5 sensor 
chip surface, increasing concentration of LPS-EB (3.125-100 nM) diluted in running buffer were injected over 
immobilized IFI16. Data are representative of three independent experiments. (E) Ex-vivo interaction analysis between 
increasing amount of recombinant IFI16 and formalin-fixed gram-negative (E. coli and K. pneumonia; pink circles and 
pink squares, respectively) or gram-positive (S. aureus, S. epidermidis, S. pyogenes; blue circles, squares and triangles, 
respectively) bacteria. Data are expressed as mean values ± SD of three independent experiments. (F) Lipid A structures 
of LPS derived from E. coli O111:B4 or F583 LPS (LPS-EB and LPS-F583, respectively; strong TLR4 agonists), P. 
gingivalis (LPS-PG; weak TLR4 agonist) and R. sphaeroides (LPS-RS, TLR4 antagonist). For LPS-PG, which harbors a 
mixture of di-, mono- and de-phosphorylated penta- or tetra-acylated lipid A moieties, a single isoform is represented for 
simplicity. PS-outer chain = polysaccharide outer chain. (G) Saturation binding experiments with increasing amount of 
recombinant IFI16 (8 to 12,288 ng/ml) and 10 µg/ml of LPS-EB (red line), LPS-F583 (green line), LPS-PG (blue line) or 
LPS-RS (purple line). Anti-IFI16 antibodies against the N-terminus of the protein and HRP-labelled anti-rabbit IgG were 
added as primary and secondary antibody, respectively, and binding was detected by ELISA at 450 nm. Data are expressed 
as mean values ± SD of three independent experiments. 
 
 
4.2. IFI16 binds to the lipid A moiety of LPS through its HINB domain 
To identify which LPS moiety is involved in IFI16 binding, we performed saturation binding 
experiments using two different variants of lipid A derived from the E. coli F583 strain, namely 
diphosphorylated and monophosphorylated lipid A (DPLA and MPLA, respectively), alongside 
a detoxified LPS molecule derived from the E. coli strain O111:B4 (detoxLPS) (Fig 7A). The first 
two molecules lack the heteropolysaccharide outer chain and differ in the number of phosphate 
groups, with MPLA being a weaker agonist than DPLA (Casella and Mitchell, 2013). On the 
other hand, the detoxLPS lipid A moiety is partially delipidated by alkaline hydrolysis, resulting 
in only four primary acyl chains being directly esterified with the sugar moiety, in which the outer 
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chain is however preserved. DetoxLPS endotoxin levels are about 10,000 times lower than that 
of parental LPS (Wähämaa et al., 2011). As shown in Fig 7B, IFI16 readily bound to both forms 
of lipid A in a concentration-dependent fashion. The KD values showed higher affinity for the 
lipid A moieties (either form) in comparison with LPS-F583—0.9 nM and 1.2 nM, respectively, 
vs. 4.3 nM (Table 2). Interestingly, the KD value for IFI16 binding to detoxLPS (55.6 nM) was 
the highest among all LPS forms, indicating that the canonical acyl chain is required for IFI16 
binding to LPS. When lipid A was pre-treated with PMB, no signal was detected. Thus, LPS binds 
to IFI16 through its lipid A moiety. To corroborate these data, a competition ELISA was 
performed by immobilizing LPS from the E. coli strain O111:B4 (LPS-EB) onto the microtiter 
plates followed by the addition of a mixture of a constant amount of IFI16 and increasing 
concentrations of LPS-EB, MPLA or detoxLPS, in this case used as competitors. As expected, 
addition of LPS-EB reduced IFI16 binding to immobilized LPS in a concentration-dependent 
manner (Fig 7C, white bars). Interestingly, a concentration of 5 g/ml of MPLA was sufficient 
enough to achieve a much stronger reduction in IFI16 binding to LPS compared to a similar dose 
of LPS-EB (Fig 7, grey bars). Binding inhibition was further enhanced at higher concentrations 
of MPLA, but the difference between the two variants was less evident. By contrast, detoxLPS 
did not interfere with the binding of IFI16 to the canonical agonist LPS, even at the highest 
concentrations used (25 g/ml: LPS-EB vs. detoxLPS, P = 0.0059; MPLA vs. detoxLPS, P < 
0.0004; LPS-EB vs. MPLA, ns; unpaired t-test) (Fig 7, black bars). Taken together, these findings 
indicate that lipid A is the LPS moiety involved in the binding to IFI16 and that the 
heteropolysaccharide outer chain, absent in MPLA, might constitute a steric hindrance for such 
interaction. 
To identify the domain of IFI16 mediating binding to LPS, an in vitro pull-down assay was 
performed using three distinct recombinant domains of IFI16 spanning either the N-terminal 
portion containing the pyrin domain (PYRIN) or each of the 200 amino acid-long HIN domains 
(namely HINA or HINB) (Fig 7D). As shown in Fig 7E, a signal at ~35 kDa was only detected 
44 
 
when the HINB fragment was incubated with biotin-LPS-EB bound to streptavidin beads (lane 
9), while neither the PYRIN nor the HINA fragment was co-precipitated in the presence of 





Fig 7. IFI16 binds to the lipid A moiety of LPS through its HINB domain. (A) Structures of di- or mono-
phosphorylated lipid A from E. coli F583 (DPLA and MPLA, respectively) and detoxified LPS (detox-LPS) derived from 
E. coli O111:B4. PS-outer chain = polysaccharide outer chain. (B) Saturation binding experiments with increasing amount 
of recombinant IFI16 (from 8 to 12,288 ng/ml) and 10 µg/ml of MPLA (green line), DPLA (red line) or detox-LPS (purple 
line). Binding was detected by ELISA as described in the legend to Fig 7G. Data are expressed as mean values ± SD of 
three different experiments. (C) Competition ELISA assay for LPS-EB binding to IFI16 with increasing amount of LPS-
EB, MPLA or detox-LPS as competitors. Briefly, microtiter plates were coated with 1 µg/ml LPS-EB, then 2 µg/ml of 
IFI16 were added to the wells in the presence of increasing concentration (5 to 25 g/ml) of competitor. Binding was 
detected by ELISA as described in the legend to Fig 7F. Data are expressed as mean values ± SD of three independent 
experiments (***P<0.001, **P<0.01, Student’s t test). (D) Domain organization of the IFI16 protein. The numbers 
represent the amino acid positions based on NCBI Reference Sequence NP_005522. From the N- to the C-terminal (left 
to right), IFI16 comprises a pyrin domain involved in protein-protein interaction, and two hematopoietic interferon-
inducible nuclear protein with 200-amino-acid repeats (HINA and HINB) domains, which are a hallmark of the absent in 
melanoma 2-like receptors (ALRs). S/T/P = serine/threonine/proline-rich repeats, which are regulated by alternative 
mRNA splicing. (E) Coomassie brilliant blue staining of pull-down assays performed with 3 g of recombinant PYRIN, 
HINA, and HINB domains, in presence or absence of biotin-labeled LPS from E. coli O111:B4 (biotin-LPS-EB). (F) 
Saturation binding experiments performed by using increasing amount (8 to 4096 ng/ml) of recombinant PYRIN, HINA 
or HINB domains (orange, purple and blue lines, respectively) and 10 µg/ml of LPS-EB, LPS-PG, MPLA or DPLA. Anti-
IFI16 antibodies against the N- or C-terminus of the protein and HRP-labeled anti-rabbit IgG were added as primary and 
secondary antibody, respectively, and binding detected in ELISA at 450 nm. Data are expressed as mean values ± SD of 
three independent experiments. 
 
To corroborate these data, an in vitro pull-down assay was performed using a truncated variant 
of IFI16 lacking the HINB domain (IFI16HINB) (Fig 8A). As expected, no binding was 
observed when IFI16HINB was incubated with biotin-LPS-EB and streptavidin beads (Fig 8B, 
lane 2), confirming that the HINB is required for LPS binding. To further support a role of the 
HINB domain in mediating the binding of IFI16 to LPS, we performed saturation binding 
experiments using increasing concentrations of the three IFI16 domains (i.e., PYRIN, HINA, and 
HINB) with fixed amounts of different interactors. As shown in Fig 7F (blue lines), the HINB 
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domain was able to bind to both LPS variants, displaying either strong or weak TLR4 agonist 
activity, as well as to lipid A. The binding was not affected by the origin of bacterial LPS or by 
the number of phosphate groups, and displayed KD values in a similar range to that obtained with 
the full-length recombinant IFI16 protein (Table 2). Conversely, the PYRIN (orange lines) and 
HINA (purple lines) domains displayed very low affinity for the immobilized molecules when 
compared to HINB, with KD values indicative of unspecific binding (Table 2). Thus, the HINB 
domain displays the highest affinity for LPS, indicating that HINB may play a major role in the 
interaction between IFI16 and LPS. 
 
 
Fig 8. IFI16 variant lacking HINB domain does not bind to LPS. (A) Domain organization of the IFI16ΔHINB protein. 
The numbers represent the amino acid positions based on NCBI Reference Sequence NP_005522. From the N- to the C-
terminal (left to right), IFI16ΔHINB comprises a pyrin domain, and only one hematopoietic interferon-inducible nuclear 
protein with 200-amino-acid repeats (HINA) domain. S/T/P = serine/threonine/proline-rich repeats. (B) Coomassie 
brilliant blue staining of pull-down assays performed with 3 μg of recombinant IFI16ΔHINB, full-length IFI16, or HINB 





4.3. Only potent TLR4-activating endotoxins can potentiate the proinflammatory activity 
of IFI16 
The results so far obtained prompted us to investigate whether IFI16 binding to the strong 
agonist variant LPS-EB would modulate IFI16-mediated transcriptional activation of 
proinflammatory cytokines in vitro. For these experiments, in addition to the standard human 
monocytic cell line THP-1, we chose as a model the renal tubular carcinoma cell line 786-O. We 
first assessed protein expression levels of the main components of the LPS recognition complex 
(i.e., TLR4, MD2, MyD88 and CD14) by Western blotting and/or flow cytometry (data not 
shown). While TLR4 and MD2 were expressed at similar levels in both cell lines, CD14 
expression was 4-fold lower in THP-1 vs. 786-O cells, as judged by FACS analysis (data not 
shown), in good agreement with a previous report (Petes et al., 2018). The expression of the TLR4 
canonical adaptor MyD88 was similar in both cell lines (data not shown).  
Next, cells were stimulated with full-length IFI16 or the IFI16HINB variant, alone or pre-
incubated with LPS-EB, and then total RNA was extracted to assess mRNA levels of a panel of 
proinflammatory cytokines (Fig 9A). Consistent with IFI16 acting as a DAMP, IL-6, IL-8 and 
tumor necrosis factor- (TNF-α) mRNA levels were strongly upregulated in cells treated with 
IFI16 alone when compared to mock- or LPS-treated cells in the presence of either low or high 
LPS concentration. Interestingly, we detected a further increase in mRNA expression levels of 
the aforementioned genes in cells treated with the IFI16/LPS-EB complex compared to IFI16 
alone—i.e., 1.8- and 1.6-fold induction for IL-6; 1.7- and 1.3-fold induction for IL-8; and 2.1- 
and 1.6-fold induction for TNF- in 786-O and THP-1 cells, respectively. Likewise, IL-1 gene 
expression levels were also significantly induced by IFI16 alone or IFI16/LPS-EB complex 
treatment of THP-1 cells—i.e., 72- and 83-fold induction, respectively—and, albeit to a lower 
extent, 786-O cells—i.e., 13- and 27-fold induction, respectively. When IFI16HINB alone or 
pre-incubated with LPS-EB was used to stimulate the cells, the degree of cytokine induction was 
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similar to that observed with the full-length protein, while it was not enhanced following pre-
incubation with LPS-EB. 
Altogether, these findings further strengthen the notion that the HINB moiety is necessary for 
the formation of the functional IFI16/LPS complex. 
Consistent with the mRNA data, the amounts of IL-6, IL-8 and TNF- secreted into the 
culture supernatants were significantly higher in cells treated with the IFI16/LPS-EB complex 
than those of cells treated with IFI16 alone, while they did not vary upon pre-incubation with 
LPS-EB in the case of the IFI16HINB variant (Fig 9B). In contrast, neither IFI16 nor 
IFI16HINB per se or after forming a complex with LPS induced IL-1 release in both cell lines, 
indicating lack of inflammasome-mediated IL-1 processing at 24 h post-treatment.  
 
Fig 9. IFI16 proinflammatory activity is potentiated by the strong TLR4 activator LPS-EB. (A) qRT-PCR analysis 
of IL-6, IL-8, TNF-α and IL-1 mRNA expression levels in 786-O or THP-1 cells stimulated for 24 h with IFI16 
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(25 µg/ml), IFI16ΔHINB (25 µg/ml), LPS from E. coli O111:B4 (LPS-EB, 10 ng/ml or 1 g/ml), IFI16/LPS-EB complex 
(preincubated O/N at 4°C), IFI16ΔHINB/LPS-EB (preincubated O/N at 4°C), or left untreated (mock). Values are 
normalized to GAPDH mRNA and plotted as fold induction over mock-treated cells. qRT-PCR data are presented as 
mean values of biological triplicates. Error bars indicate SD (*P < 0.05, **P < 0.01, ***P < 0.001; two-way ANOVA 
followed by Dunnett’s test). (B) Protein concentration of IL-6, IL-8 and TNF-α evaluated by ELISA in supernatants 
derived from 786-O or THP-1 cells stimulated for 24 h as described in A. Data are expressed as mean values ±SD of three 
independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001; two-way ANOVA followed by Dunnett’s test).  
 
Next, we asked whether the LPS derivatives DPLA and MPLA or the TLR4 antagonist LPS-
RS would be equally able to modulate the biological activity of IFI16. The full agonist LPS-F583, 
from which DPLA and MPLA were derived, was included as positive control (full TLR4 
activator). Cells were treated with the aforementioned compounds, alone or pre-complexed with 
IFI16 protein, and then total RNA and supernatants were collected to assess the mRNA expression 
and cytokine production profiles of IL-6, IL-8 and TNF-. As expected, cells treated with the 
IFI16/LPS-F583 displayed a similar transcriptional activation pattern to that previously observed 
in IFI16/LPS-EB-treated cells (Fig 10A). On the other hand, when cells were treated with IFI16 
complexed with LPS-RS, MPLA or DPLA, we failed to observe any transcriptional enhancement 
in comparison with IFI16 alone. A similar pattern was found when the same cytokines were 
measured in the culture supernatants by ELISA (Fig 10B), although a significant increase in 
IFI16-induced secretion of IL-6 and IL-8 was only observed when cells were treated with the 
IFI16-DPLA complex—i.e., 1.4-fold induction for IL-6 in THP-1 cells, 1.3- and 1.8-fold 
induction for IL-8 in 786-O and THP-1, respectively.  
Collectively, these data indicate that the proinflammatory activity of full-length IFI16 is 
potentiated when this protein is complexed with potent TLR4-activating LPS variants via the 
HINB moiety, while it is not affected when it forms a complex with the TLR4 antagonist LPS-





Fig 10. Weak TLR4-activating LPS variants and the TLR4 antagonist LPS-RS do not potentiate IFI16 
proinflammatory activity. (A) qRT-PCR analysis of IL-6, IL-8 and TNF-α mRNA expression levels in 786-O or THP-
1 cells stimulated for 24 h with or without IFI16 (25 µg/ml), LPS from E. coli F583 (LPS-F583, 10 ng/ml) or LPS from 
R. sphaeroides (LPS-RS, 10 ng/ml), MPLA (10 ng/ml), DPLA (10 ng/ml) or in the presence of one of the following 
complexes: IFI16/LPS-F583, IFI16/LPS-RS, IFI16/MPLA or IFI16/DPLA. Values are normalized to GAPDH mRNA 
and plotted as fold induction over mock-treated cells. qRT-PCR data are presented as mean values of biological triplicates. 
Error bars indicate SD, and the P values refer to comparisons between IFI16 vs. IFI16/LPS or IFI16/lipid A complex-
treated cells (*P < 0.05, **P < 0.01, ***P < 0.001; two-way ANOVA followed by Dunnett’s test). (B) Protein 
concentration of IL-6, IL-8 and TNF-α evaluated by ELISA in supernatants derived from 786-O or THP-1 cells stimulated 
for 24 h as described in the legend to panel A. Data are expressed as mean values ±SD of three independent experiments 
(*P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant; two-way ANOVA followed by Dunnett’s test). The P values 
are relative to comparisons between IFI16- and IFI16/LPS- or IFI16/lipid A-treated cells. 
 
4.4. IFI16 exerts its proinflammatory activity in a TLR4/MyD88-dependent fashion 
Since we had previously implicated TLR4 signaling in IFI16-mediated cytokine release in 
endothelial cells (Bawadekar et al., 2015b), we sought to determine whether ablation of the 
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TLR4/MD2 complex would affect IFI16/LPS proinflammatory activity. To this end, we 
performed gene silencing of TLR4 and MD2 genes in both 786-O and THP-1 cells, achieving 
complete knockdown of both genes, as judged by immunoblotting and flow cytometric analysis 
(data not shown). As shown in Fig 11, the transcriptional activation of IL-6, IL-8 and TNF- 
genes (panels A and B) as well as the release of the same cytokines (Fig 12 A, B) in the culture 
supernatants upon exposure to both IFI16 or IFI16/LPS-EB was almost completely abolished in 
siTLR4- and siMD2-silenced cells when compared to siRNA control (siCTRL)-transfected cells. 
Similar results were obtained in both 786-O and THP-1 cells, indicating that IFI16 signaling 
through the TLR4-MD2 complex is not cell type-specific.  
Upon LPS stimulation, TLR4 induces two independent signaling pathways regulated by either 
the TIRAP/MyD88 or TRAM/TRIF pair of adaptors, which promote the production of 
proinflammatory cytokines and type I interferons (IFN-I), respectively (Kagan, 2017; Takeda and 
Akira, 2004). As IFN- could never be detected in IFI16- or IFI16/LPS-stimulated cells, we 
assumed that the TRAM-TRIF pathway would not play a role in our model. To address a potential 
role of the TIRAP-MyD88 complex, we performed siRNA-mediated knockdown of MyD88 in 
both 786-O and THP-1 cells (data not shown). In MyD88-silenced cells treated with IFI16 alone 
or IFI16/LPS-EB, transcription of IL-6, IL-8 and TNF- genes (Fig 11C) and release of the 
corresponding cytokines (Fig 12C) were dramatically reduced in comparison with siCTRL-
transfected cells, indicating that IFI16 or the IFI16/LPS complex signals through the TIRAP-
MyD88 axis. Fittingly, ELISA-based transcription factor binding assay, performed using a probe 
containing the NF-κB binding site (Fig 12D), showed NF-B binding activity to be significantly 
increased in cells challenged with IFI16 alone or pre-complexed with LPS-EB in comparison with 
untreated cells—i.e., 2.2- and 3.9-fold induction in 786-O cells; 2.4- and 2.9-fold induction in 
THP-1 cells, respectively (Fig 12E). Overall, these results demonstrate that IFI16-mediated 
proinflammatory cytokine production requires the TLR4-MD2/TIRAP-MyD88 signaling 




Fig 11. Quantitative RT-PCR analysis of proinflammatory cytokine expression in TLR4, MD2 and MyD88 
knockdown cells. (A-C) qRT-PCR analysis of IL-6, IL-8 and TNF-α mRNA expression levels in 786-O or THP-1 cells 
transfected for 48 h with scramble control (siCTRL), or siRNAs against TLR4 (siTLR4) (A), MD2 (siMD2) (B) or 
MyD88 (siMyD88) (C). Cells were then stimulated for 24 h with IFI16 (25 µg/ml), LPS from E. coli O111:B4 (LPS-EB, 
10 ng/ml) or IFI16/LPS-EB complex (preincubated O/N at 4°C), or left untreated (mock). Values were normalized to 
GAPDH mRNA and plotted as fold induction over mock-treated cells. qRT-PCR data are expressed as mean values of 
biological triplicates. Error bars indicate SD (*P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant; unpaired Student’s 





Fig 12. IFI16 exerts its proinflammatory activity in a TLR4/MyD88-dependent fashion. (A-C) Protein concentration 
of IL-6, IL-8 and TNF-α measured by ELISA in supernatants derived from 786-O or THP-1 cells transfected for 48 h 
with scramble control (siCTRL), or siRNAs against TLR4 (siTLR4, A), MD2 (siMD2, B) or MyD88 (siMyD88, C). Cells 
were then stimulated for 24 h with IFI16 (25 µg/ml), LPS from E. coli O111:B4 (LPS-EB, 10 ng/ml) or IFI16/LPS-EB 
complex (preincubated O/N at 4°C), or left untreated (mock). Data are expressed as mean values ± SD of three 
independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant; unpaired Student’s t-test for 
comparison of silenced cells vs. their relative control counterpart). (D) Schematic representation of the probe containing 
the NF-κB binding site (highlighted in grey). (E) 786-O cells or THP-1 cells were stimulated with IFI16 (25 µg/ml), LPS 
from E. coli O111:B4 (LPS-EB, 10 ng/ml) or IFI16/LPS-EB complex (preincubated O/N at 4°C), or left untreated (mock). 
After 2 h, the cells were lysed and the nuclear fraction was analyzed for NF-κB binding activity using the Universal EZ-
TFA transcription factor assay colorimetric kit and the probe described in D. Data are expressed as mean values ± SD of 




Finally, to circumvent potential issues of structural or functional differences between 
mammalian or bacterial expressed IFI16, we used wild-type and IFI16-knockout (IFI16-/-) human 
osteosarcoma U2OS cells as a source of endogenous IFI16 released under stress stimuli. As shown 
in Fig 13A, and consistent with our previous report (Costa et al., 2011), UVB treatment (800 Jm-
2 for 16h) led to massive release of IFI16 in the culture supernatants of U2OS cells that, as 
expected, did not occur in their IFI16-/- counterparts, thus serving as IFI16-depleted supernatant. 
The resulting conditioned media were preincubated with or without LPS-EB or LPS-RS and then 
added to THP-1 cells. After 24 h, the supernatants of the THP-1 cultures were harvested and 
assessed for cytokine expression by ELISA. Consistent with the results obtained with 
recombinant IFI16, exposure of THP-1 cells to conditioned medium from UVB-treated U2OS 
cells significantly stimulated the release of IL-6, IL-8 and TNF- by THP-1 cells when compared 
to mock-treated cells—i.e., 20.9-fold higher for IL-6; 83-fold for IL-8; and 33.4-fold for TNF-α 
(Fig 13B) When THP-1 cells were pre-treated with anti-TLR4 antibodies, the stimulatory activity 
of the conditioned medium form UVB-treated U2OS cells dropped significantly. Notably, 
cytokine release was significantly lower in THP-1 cells treated with conditioned medium from 
UVB-treated U2OS-IFI16-/- cells when compared to their UVB-treated normal counterparts—i.e., 
2.8-fold lower for IL-6; 2.7-fold for IL-8; and 2.6-fold for TNF-α—, indicating that the effects 
observed were specifically due to the secretion of IFI16 protein. Consistent with the data obtained 
with the recombinant protein, cytokine release was enhanced when the conditioned media were 
preincubated with LPS-EB and, to a higher extent, with the conditioned medium of UVB-treated 
U2OS cells when compared to that of UVB-treated U2OS-IFI16-/- cells. As expected, this 










Fig 13.  Endogenous IFI16 is released by UVB-exposed U2OS cells and triggers proinflammatory cytokines 
production in a TLR4-dependent fashion.  (A) Western blot analysis of IFI16 in culture supernatants and total 
cell extracts of UVB-exposed (0 or 800 Jm-2) U2OS or U2OS-IFI16-/- cells at 16 h after treatment. β-actin cellular 
expression was used for protein loading control. Data are representative of three independent experiments with 
similar results. (B)  Protein concentration of IL-6, IL-8 and TNF-α evaluated by ELISA in supernatants derived 
from THP-1 cells stimulated for 24 h in the presence or absence of anti-TLR4 neutralizing antibodies (10 μg/ml) 
using conditioned medium from UVB-exposed (0 or 800 Jm-2) U2OS and U2OS-IFI16-/- cells, or complete medium 
(mock), preincubated (O/N at 4°C), or not, with LPS from E. coli O111:B4 (LPS-EB, 10 ng/ml), or LPS from R. 
sphaeroides (LPS-RS, 10 ng/ml). Values were normalized to the initial protein concentration of the analyzed 
cytokines in the supernatants used for the treatment. Data are expressed as mean values ±SD of three independent 
experiments. The P values refer to comparison in each group with cells treated only with the medium without any 




4.5. IFI16 binds to TLR4 in vivo and in vitro 
We next sought to determine whether IFI16 could also bind to the TLR4/MD2 complex in 
vivo. To this end, co-immunoprecipitation assays were performed where TLR4 and interacting 
partners were immunoprecipitated using an anti-TLR4 antibody pre-adsorbed on protein G beads. 
The resulting immune complexes were then analyzed by SDS-PAGE followed by 
immunoblotting for TLR4, MD2, and IFI16. As shown in Fig 14A, IFI16 co-immunoprecipitated 
with TLR4/MD2 receptor when total extracts from cells treated with either IFI16 alone or 
IFI16/LPS-EB complex were used (lane 2 and 4, respectively). The specificity of this interaction 
was attested by the absence of co-immunoprecipitated IFI16 in extracts from cells untreated or 
treated with LPS-EB alone (lane 1 and 3, respectively). To ensure that residual DNA potentially 
present in the protein extracts would not affect Co-IPs, whole-cell extracts were treated with 
DNase and then subjected to Co-IP. As shown in Fig 14A (lane 5 and 6, respectively), the 
interaction between IFI16 or IFI16/LPS and TLR4 was maintained also in protein extracts 
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obtained from DNase-treated cells, indicating that the interaction between these molecules is not 
mediated by DNA binding.  
The specificity of the interaction between IFI16 and TLR4 was then evaluated by surface 
plasmon resonance (SPR). Briefly, recombinant TLR4 was directly immobilized on a CM5 sensor 
chip by amine coupling and then probed with increasing concentration of recombinant IFI16—
from 31.25 nM to 1 M. As shown in Fig 14B, the resulting SPR sensorgrams revealed significant 
binding between TLR4 and IFI16 with an equilibrium dissociation constant (KD) of 0.13 M and 
a kinetic profile typical of dynamically interacting partners, with the dissociation rate being 
compatible with a rapid stimulation turnover of the ligand (i.e., IFI16) on the TLR4 receptor. 
Thus, taken together these results indicate that the proinflammatory activity of IFI16, either alone 
or pre-complexed with LPS, is mediated by the TLR4/MD2/MyD88/NF-κB signaling pathways 




Fig 14. IFI16 binds to TLR4 in vitro and in vivo. (A) 786-O cells were stimulated for 1 h in the presence or absence of 
the indicated concentrations of IFI16, LPS from E. coli O111:B4 (LPS-EB), or IFI16/LPS-EB complex. Total cell 
extracts, untreated or DNase I-treated, were subjected to immunoprecipitation using a TLR4 monoclonal antibody. 
Immunoprecipitates and whole-cell lysates were analyzed by immunoblotting with anti-IFI16, anti-TLR4 or anti-MD2 
antibodies. β-actin protein expression was used for protein loading control. Data are representative of three independent 
experiments with similar results. (B) Surface plasmon resonance (SPR) analyses of IFI16 binding to immobilized TLR4. 
After immobilization of TLR4 on the CM5 sensor chip surface, increasing concentration of IFI16 (31.25-1000 nM) diluted 
59 
 
in running buffer were injected over immobilized TLR4. IFI16 binds to TLR4 with an equilibrium dissociation constant 
(KD) of 0.13 M. Data are representative of three independent experiments. 
 
 
4.6. The IFI16/LPS complex proinflammatory activity is not affected by the presence of free 
LPS.  
To gain more insights into the biological relevance of the IFI16/LPS complex vs. LPS, we 
sought to determine the proinflammatory activity of IFI16 or IFI16/LPS complex in the presence 
or absence of equal amounts of LPS simultaneously added to the cells. For this purpose, 786-O 
and THP-1 cells were stimulated with an array of different combinations as indicated in Fig 15. 
When IFI16 and LPS-EB were simultaneously added to the cells, without any pre-incubation step, 
induction of IL-6, IL-8 and TNF- at both the mRNA and protein levels (Fig 15A and B, 
respectively) was comparable to that observed using LPS-EB alone, indicating that the affinity of 
IFI16 for the TLR4/MD2 receptor is lower than that of LPS. In contrast, when LPS-EB was 
simultaneously added to the cells together with the pre-formed IFI16/LPS-EB complex, induction 
of IL-6, IL-8 and TNF- at both the mRNA and protein levels was comparable or even higher 
than that observed in cells stimulated with the IFI16/LPS-EB complex alone, suggesting that the 
affinity of the IFI16/LPS-EB complex for the TLR4 receptor is stronger than that of LPS-EB 
alone. Similar results were obtained when LPS-RS, a TLR4 antagonist, was used with the same 
combination treatment. Again, IFI16/LPS-RS complex activity, as measured by the induction of 
IL-6, IL-8 and TNF- was not affected by simultaneous addition of equal amounts of LPS-RS. 
Taken together, these findings clearly show that once IFI16 is complexed with LPS its 
proinflammatory activity is not affected by the simultaneous addition of LPS, regardless of its 
bacterial origin. 
To better clarify the dynamics of interaction between IFI16/LPS-EB complex and TLR4/MD2 
receptor, we performed further SPR analyses by means of a CM5 sensor chip coated with 
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recombinant TLR4/MD2. As shown in Table 3, the SPR-based studies demonstrated that the three 
receptor partners (i.e., IFI16, LPS-EB and the IFI16/LPS-EB complex) had association rate (Ka) 
values in the same range, with IFI16/LPS-EB showing a 3- and 2-fold faster association compared 
to IFI16 or LPS-EB alone, respectively. Interestingly, in agreement with our previous findings, 
IFI16 interacted with the TLR4/MD2 complex in a concentration-dependent manner with a KD of 
0.68 μM, as calculated by the evaluation of the sensorgrams in Fig 15C. Moreover, LPS-EB alone 
revealed a much higher affinity, with a KD of 0.15 nM. In contrast, IFI16/LPS-EB complex bound 
to TLR4/MD-2 with 6-fold lower affinity (KD = 4.01 μM) when compared to IFI16 alone. The 
lower KD displayed by LPS-EB was mainly due to the contribution of a lower dissociation rate 
constant (Kd = 1.00*10
-6 s-1), indicating that the kinetics of LPS-EB dissociation from the receptor 
is very slow. Interestingly, the sensorgrams demonstrated a much higher dissociation rate for both 
free IFI16 (Kd = 6.14*10
-3 s−1) and the IFI16/LPS-EB complex (Kd = 1.43*10
-2 s−1) in comparison 
with LPS-EB alone, indicating that bindings involving IFI16 are much less stable once formed. 
In agreement with the cytokine release, the aforementioned results indicate that, when added 
separately, LPS-EB binds to TLR4/MD2 more rapidly than IFI16 alone. In this setting, LPS-EB 
per se is able to trigger a weak inflammatory response highly likely due to its slow dissociation 
from the receptor, which in turn delays the optimal turnover of the receptor. In contrast, 
IFI16/LPS-EB complex binds to TLR4 more rapidly than LPS-EB simultaneously added to the 





Fig 15. The IFI16/LPS complex proinflammatory activity is not affected by the presence of free LPS. (A) qRT-PCR 
analysis of IL-6, IL-8, TNF-α and mRNA expression levels in 786-O or THP-1 cells stimulated for 24 h with IFI16 
(25 µg/ml), LPS from E. coli O111:B4 (LPS-EB, 10 ng/ml), IFI16/LPS-EB complex, IFI16 + LPS-EB (not complexed), 
IFI16/LPS-EB complex + LPS-EB (10 ng/ml), LPS from Rhodobacter sphaeroides (LPS-RS, 10 ng/ml), IFI16/LPS-RS 
complex, IFI16 + LPS-RS (not complexed), IFI16/LPS-RS complex + LPS-RS (10 ng/ml), or left untreated (mock). 
Values were normalized to GAPDH mRNA and plotted as fold induction over mock-treated cells. The P values refer to 
comparisons with IFI16-treated cells (*P < 0.05, **P < 0.01, ***P < 0.001; one-way ANOVA followed by Dunnett’s 
test). (B) Protein concentration of IL-6, IL-8 and TNF-α was measured by ELISA in supernatants derived from 786-O or 
THP-1 cells stimulated for 24 h as described in a. Data are expressed as mean values ±SD of three independent 
experiments. The P values refer to comparisons with IFI16-treated cells (*P < 0.05, **P < 0.01, ***P < 0.001; one-way 
ANOVA followed by Dunnett’s test). (C) Surface plasmon resonance (SPR) analyses of IFI16, LPS-EB and IFI16/LPS-
EB complex binding to immobilized TLR4/MD2 receptor. After immobilization of recombinant TLR4/MD2 on the CM5 
sensor chip surface, increasing concentration of the different analytes—31.25-1000 nM for IFI16, 3.125-100 µM for LPS-
EB, 31.25-1000 nM for IFI16/LPS-EB complex—diluted in running buffer were injected over immobilized TLR4/MD2. 
IFI16, LPS-EB, and IFI16/LPS-EB bind to TLR4/MD2 with an equilibrium dissociation constant (KD) of 0.68 μM, 0.15 





Table 3. Binding kinetics of IFI16, LPS-EB and IFI16/LPS-EB to TLR4/MD2 receptor 
 Ka (1/Ms) Kd (1/s) KD (M) Rmax (RU) Chi
2
 (RU) 
IFI16 9.07*103 6.14*10-3 6.77*10-7 26.09 1.83 
LPS-EB 6.84*103 1.00*10-6 1.47*10-10 745.00 14.30 
IFI16/LPS-EB 3.57*103 1.43*10-2 4.01*10-6 90.30 6.89 
Ka, association rate constant; M, molarity; s, seconds; Kd, dissociation rate constant; KD, equilibrium 
dissociation constant; Rmax, maximum response; RU, response units; Chi2, average squared residual. 
 
4.7. The human IFI16 protein equally activates murine TLR4 
Despite the huge number of murine HIN200 genes and pseudogenes, no data are currently 
available to demonstrate a clear counterpart for IFI16 in mice (Brunette et al., 2012; Deschamps 
et al., 2003). In order to establish a reliable in vivo model to test the IFI16 pro-inflammatory 
activity, and since human TLR4 and murine TLR4 display about 65% of homology (Hajjar et 
al., 2002), we aimed to determine whether human IFI16 could interact with murine TLR4. To 
this end, RAW 264.7 murine macrophages were treated with IFI16 and co-immunoprecipitation 
assays were performed immunoprecipitating TLR4 and interacting partners, as previously done. 
The resulting immune complexes were then analyzed by SDS-PAGE followed by 
immunoblotting for TLR4 and IFI16. As shown in Fig 16A, IFI16 co-immunoprecipitated with 
TLR4 receptor when total extracts from IFI16-treated cells were used. The specificity of this 
interaction was confirmed by the absence of co-immunoprecipitated IFI16 in extracts from 
untreated cells. As expected, there were no IFI16 bands in the input control of untreated cells, 
while IFI16 was clearly detectable in the input control of IFI16-treated cells. To further 
strengthen these results, RAW 264.7 cells were stimulated with full-length IFI16 and then total 
RNA was extracted to assess mRNA levels of IL-6 and IL-1β as read-out proinflammatory 
cytokines (Fig 16B). Interestingly, the results obtained were fully consistent with those found in 
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human cells. Indeed, IL-6 and IL-1β mRNA levels were strongly upregulated in cells treated with 
IFI16 when compared to mock-treated cells —i.e., 359.7-fold higher for IL-6; 547.7-fold for IL-
1β. Finally, to directly prove that the extracellular IFI16 released by human cells could lead to 
inflammatory activation in murine cells, we used the conditioned media from untreated or UVB-
treated U2OS and U2OS-IFI16-/- cells as a source of endogenous IFI16 (Fig 13A). Consistent 
with the results obtained with recombinant IFI16, exposure of RAW 264.7 cells to conditioned 
medium from UVB-treated U2OS cells containing extracellular IFI16 caused a significant 
upregulation in the IL-6 and IL-1β mRNA levels when compared to untreated cells —i.e., 124-
fold higher for IL-6; 169.9-fold for IL-1β (Fig 16C). 
Collectively, these results strongly suggest that IFI16 binds and activates also the murine 
TLR4/MD2 receptor, offering the opportunity of investigating the pro-inflammatory activity of 
IFI16 in mouse models.  
 
Fig 16. The human IFI16 protein equally activates murine TLR4. (A) RAW 264.7 cells were stimulated for 1 h in the 
presence or absence of the indicated concentration of IFI16. Total cell extracts were subjected to immunoprecipitation 
using a TLR4 monoclonal antibody. Immunoprecipitates and whole-cell lysates were analyzed by immunoblotting with 
anti-IFI16 or anti-TLR4 antibodies. β-actin protein expression was used for protein loading control. Data are 
representative of three independent experiments with similar results. (B) qRT-PCR analysis of IL-6 (left panel) and IL-
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1β (right panel) mRNA expression levels in RAW264.7 mouse macrophages stimulated for 4 and 24 h with IFI16 (10 
μg/ml) or left untreated (mock). Values are normalized to β-actin mRNA and plotted as fold of induction over mock-
treated cells. qRT-PCR data are presented as mean values of biological triplicates. Error bars indicate SD (**P < 0.01, 
***P < 0.001; unpaired t-test with Welch's correction). (C) qRT-PCR analysis of IL-6 and IL-β mRNA expression levels 
in RAW264.7 mouse macrophages stimulated for 24 h with conditioned medium from UVB-exposed (0 or 800 Jm-2) 
U2OS and U2OS-IFI16-/- cells or with complete medium (mock). Values are normalized to β-actin mRNA and plotted as 
fold of induction over mock-treated cells. qRT-PCR data are shown as mean values of biological triplicates. Error bars 
indicate SD (*P < 0.05, **P < 0.01, ***P < 0.001; one-way ANOVA followed by Dunnett’s test). 
 
4.8. The PYRIN domain of IFI16 mediates TLR4 activation 
Since previous work from our group demonstrated that the IFI16 N-terminal domain mediates 
its binding to the cell membrane of HUVEC (Gugliesi et al., 2013), we sought to determine 
whether IFI16 N-terminal domain inhibition could result in reduced levels of pro-inflammatory 
activity. To this end, RAW 264.7 cells were stimulated with different concentrations of full-length 
IFI16, alone or pre-incubated with increasing concentrations of rabbit polyclonal anti-IFI16 N-
term antibodies, and then total RNA was extracted to assess mRNA levels of IL-6 and IL-1β. 
Consistent with our previous results, IL-6 and IL-1β mRNA levels were strongly upregulated in 
RAW 264.7 cells treated with all the concentrations of IFI16 tested. Interestingly, anti-IFI16 N-
term antibodies significantly inhibited IFI16-mediated IL-6 and IL-1β upregulation in a 
concentration-dependent manner (Fig 17A). Accordingly, anti-IFI16 C-term antibodies did not 
have any effect on IFI16 proinflammatory activity (data not shown).  
Next, to understand whether the inhibitory capability of anti-IFI16 N-term antibodies was 
associated with a reduced interaction between IFI16 and TLR4/MD2 receptor, SPR analyses were 
performed. As shown in Fig 17B, IFI16 bound to TLR4/MD2 receptor giving a response units 
(RUs) value of about 40. Interestingly, anti-IFI16 N-term antibodies significantly inhibited IFI16 
binding to its receptor (about 75% of reduction when the highest concentration was used). In 
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contrast, anti-IFI16 C-term antibodies, even at the highest concentration, did not inhibit IFI16 
binding to the receptor. Altogether, these data demonstrate that the IFI16 pro-inflammatory 
activity lies within its N-terminal portion. 
These results prompted us to better characterize the pro-inflammatory activity of the N-
terminal PYRIN domain of IFI16 (Chu et al., 2015; Jin et al., 2013). To this end, 786-O cells were 
stimulated with 25 μg/ml of full-length IFI16 or with equimolar concentrations of PYRIN, HINA 
and HINB domains (277 nM). As a control, IFI16HINB and IFI16PYRIN variants were used. 
Total RNA extracts prepared at 24h post-treatment were used to assess mRNA expression levels 
of IL-6, IL-8, and TNF-α genes. Consistent with the data previously obtained, IL-6, IL-8, and 
TNF-α mRNA were strongly upregulated when the full-length IFI16 or the IFI16HINB variant 
were used (Fig 17C). By contrast, the IFI16 pro-inflammatory activity was strongly reduced when 
IFI16PYRIN variant was added. Interestingly, out of the three IFI16 domains, only PYRIN 
domain still retained the ability to induce IL-6, IL-8, and TNF-α mRNA upregulation, although 
at a lower extent when compared to the full-length protein —i.e., 23- fold higher for IL-6; 22-fold 
for IL-8, and 6-fold for TNF-α, respectively, compared to mock-treated cells (Fig 17C). 
Moreover, the same trend of pro-inflammatory activation was also confirmed when murine cells 
(i.e., RAW 264.7) were used, suggesting that the mechanisms of activation are conserved across 
species (Fig 17D). 
Taken together, these data strongly suggest that the IFI16 PYRIN domain is necessary and 




Fig 17. The PYRIN domain of IFI16 mediates TLR4 activation. (A) qRT-PCR analysis of IL-6 (left panel) and IL-1β 
(right panel) mRNA expression levels in RAW264.7 mouse macrophages stimulated for 24 h with IFI16 (10 μg/ml or 5 
μg/ml) alone, or preincubated with the indicated concentrations of anti-IFI16 N-term antibodies, or left untreated (mock). 
Values are normalized to β-actin mRNA and plotted as fold of induction over mock-treated cells. qRT-PCR data are 
presented as mean values of biological triplicates. Error bars indicate SD (**P < 0.01, ***P < 0.001; one-way ANOVA 
followed by Dunnett’s test). (B) Surface plasmon resonance (SPR) analyses of IFI16 binding to immobilized TLR4/MD2 
receptor, in presence of anti-IFI16 N-term or C-term antibodies. After immobilization of recombinant TLR4/MD2 on the 
CM5 sensor chip surface, 500 nM of IFI16 alone or preincubated with different concentrations of anti-IFI16 N-term 
antibodies—500-62.5 nM— or C-term antibodies—500 nM— diluted in running buffer were injected over immobilized 
TLR4/MD2. The response units (left panel) and the relative binding inhibition compared to IFI16 alone (right panel) are 
shown. Data are representative of three independent experiments. (C) qRT-PCR analysis of IL-6, IL-8, and TNF-α mRNA 
expression levels in 786-O cells stimulated for 24 h with IFI16 (25 µg/ml, 277 nM), IFI16ΔHINB (277 nM), 
IFI16ΔPYRIN (277 nM), PYRIN (277 nM), HINA (277 nM), HINB (277 nM), or left untreated (mock). Values are 
normalized to GAPDH mRNA and plotted as fold induction over mock-treated cells. qRT-PCR data are presented as 
mean values of biological triplicates. Error bars indicate SD (***P < 0.01, ***P < 0.001 relative to mock-treated cells; 
one-way ANOVA followed by Dunnett’s test). (D) qRT-PCR analysis of IL-6 and IL-1β mRNA expression levels in 
RAW264.7 mouse macrophages stimulated for 24 h with IFI16 (10 µg/ml, 111 nM), IFI16ΔHINB (111 nM), 
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IFI16ΔPYRIN (111 nM), PYRIN (111 nM), HINA (111 nM), HINB (111 nM), or left untreated (mock). Values are 
normalized to β-actin mRNA and plotted as fold of induction over mock-treated cells. qRT-PCR data are presented as 
mean values of biological triplicates. Error bars indicate SD (***P < 0.001 relative to mock-treated cells; one-way 


























We previously reported that extracellular IFI16 promotes IL-6 and IL-8 production in endothelial 
cells, and that such proinflammatory activity is amplified in the presence of subtoxic concentrations 
of LPS-EB, a full activator of the TLR4 signaling pathway (Bawadekar et al., 2015b). Here, we 
expand on those observations by showing that, in renal and monocytic cell lines, IFI16 either alone 
or in complex with LPS binds to TLR4, thereby triggering a proinflammatory response through the 
TLR4/MD2/MyD88 signaling pathway. Specifically, by means of in vitro pull-down assays and 
saturation binding experiments, we provide the first evidence that the HINB domain of IFI16 mediates 
complex formation with LPS-EB or LPS-F583, two E. coli-derived variants of LPS capable of acting 
as strong TLR4 agonists (Bryant et al., 2010; Gao et al., 2006). This interaction follows a prototypical 
associative binding, with increasing rate of binding up to the plateau phase following addition of 
increasing amounts of the analytes. Furthermore, this binding is not dependent on the polysaccharide 
outer chain length as both LPS-EB and LPS-F583 display similar binding affinity for IFI16—the 
LPS-F583 variant is in fact characterized by the presence of a shorter polysaccharide chain compared 
to that of LPS-EB (Plevin et al., 2016). In addition, we show that both LPS-PG, a weak TLR4 agonist 
(Darveau et al., 2004), and LPS-RS, a TLR4 antagonist (Anwar et al., 2015)—these molecules display 
fewer acyl chains in their lipid A moieties compared to LPS-EB—, bind to IFI16 with similar 
affinities, albeit slightly lower than those of LPS-EB and LPS-F583. Finally, using the E. coli F583-
derived DPLA and MPLA lipid A variants (Plevin et al., 2016; Stoddard et al., 2010), we demonstrate 
that lipid A is the LPS moiety interacting with IFI16-HINB, affording the highest affinity for LPS. 
Accordingly, the detoxified variant of LPS-EB, containing a lipid A moiety partially delipidated by 
alkaline hydrolysis, binds weakly to IFI16. The observation that the HINB domain of IFI16 has a 
much higher affinity for lipid A than that of the HINA domain, despite both molecules being highly 
similar in terms of primary sequence and overall structure topology, is only partially unexpected. 
Indeed, these two IFI16 domains have already been shown to have distinct modes of binding to 
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another paradigmatic PAMP—i.e., viral DNA—most likely due to their different folding structures 
(Ni et al., 2016; Unterholzner et al., 2010).  
In recent years, mounting evidence has shown how TLRs, besides sensing exogenous microbial 
components, are also capable of recognizing endogenous material released during cellular injury, 
thereby promoting a non-microbial-induced inflammatory state known as sterile inflammation, which 
if not resolved can lead to severe acute and chronic inflammatory conditions (Piccinini and Midwood, 
2010; Rifkin et al., 2005; Schaefer, 2014). Here, we propose that IFI16 might represent a novel trigger 
of sterile inflammation acting through the TLR4 signaling pathway. In particular, we show that 
exposure to recombinant IFI16 can induce IL-6, IL-8 and TNF- transcriptional activation and release 
of these cytokines into the culture supernatants. This induction is strictly dependent on the presence 
of the TLR4/MD2 receptor complex and the MyD88 adaptor. By contrast, the membrane-associated 
CD14 receptor seems to be only marginally involved in this signaling pathway given that 
undifferentiated THP-1 cells, displaying low levels of CD14 expression, and 786-O cells, expressing 
high levels of CD14, show similar cytokine induction patterns upon IFI16 exposure. The fact that 
IFI16 broadly activates inflammation through TLR4 signaling pathways strengthens the notion that 
extracellular IFI16 acts as a DAMP capable of promoting inflammation. Fittingly, aberrant IFI16 
expression—i.e., overexpression of IFI16 in otherwise negative cells or IFI16 delocalization to the 
cytoplasm—has been reported in a number of inflammatory conditions, such as SLE (skin, Costa et 
al., 2011), psoriasis (skin, Cao et al., 2016; Chiliveru et al., 2014; Tervaniemi et al., 2016), SSc (skin,  
Mondini et al., 2006), IBD (colonic epithelium, Caneparo et al., 2016; Vanhove et al., 2015) and SS 
(salivary epithelial and inflammatory infiltrating cells, Alunno et al., 2015, 2016; Antiochos et al., 
2018). Additionally, aberrant IFI16 expression has been reported in virus-infected cells (Cigno et al., 
2015; Dell’Oste et al., 2014; Singh et al., 2013) or cells treated with IFN-γ (Caposio et al., 2007). 
Importantly, in some of these and other pathological conditions, we and others have shown that IFI16 
exists in a free, extracellular form in the blood or extracellular milieu (Alunno et al., 2015, 2016; 
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Antiochos et al., 2018; Gugliesi et al., 2013). Particularly, we found that high levels of circulating 
IFI16 (≥ 27 ng/ml) were associated to overall worse clinical parameters in three cohorts of RA, SS 
and PsA patients. Notably, among RA patients, circulating IFI16 was more frequently found in 
subjects with rheumatoid factor (RF)/anti-CCP-positive serum and significantly associated with 
pulmonary involvement (Alunno et al., 2016). Furthermore, in SS patients, circulating IFI16 is 
associated with increased prevalence of both RF and glandular infiltration degree (Alunno et al., 
2015), while in PsA patients is associated with elevated C-reactive protein (CRP) levels (De Andrea 
et al., 2020). The release of extracellular IFI16 has also been shown by our group in a model of 
keratinocytes exposed to UVB radiation (Costa et al., 2011). Although the biological rationale of 
these findings is far from being completely understood, these observations clearly indicate that the 
IFI16 protein, whose expression in the natural setting is restricted to the nuclei of a limited number 
of cell types, such as keratinocytes, fibroblasts, endothelial and hematopoietic cells (Gariglio et al., 
2002), can be released by a broad spectrum of injured cells, including damaged epithelial cells or the 
inflammatory cells recruited at the site of injury, which are known to massively express IFI16. In this 
setting, as mentioned above, extracellular IFI16 can act as a DAMP in promoting sterile inflammation 
(Gong et al., 2020). Accordingly, the exposure of THP-1 cells to conditioned medium from UVB-
treated cells containing the IFI16 protein was able to significantly enhanced IL-6, IL-8 and TNF-α 
release when compared to the conditioned medium from UVB-treated IFI16 knockout cells. Addition 
of LPS-EB but not that of the weak TLR4-agonist LPS variant further enhanced cytokine induction, 
while pre-treatment of THP-1 cells with anti-TLR4 antibodies almost abolished the cytokine release. 
Thus, it is tempting to speculate that, similarly to pathogen-induced inflammation, binding of 
extracellularly-released IFI16 to TLR4 can activate both non-immune and innate immune cells, thus 
leading to the production of various cytokines and chemokines responsible for the recruitment of 
additional inflammatory cells (Chen and Nuñez, 2010). Interestingly, IFI16 pro-inflammatory activity 
lies within its PYRIN domain, which is necessary and sufficient to induce overexpression of pro-
inflammatory cytokines. Since there are more than 20 PYRIN-containing proteins in the human 
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genome (Kwon et al., 2012), most of which shares several residues in their PYRIN domains (Jin et 
al., 2013), this result could pave the way toward the identification of a new class of DAMPs, which 
once extracellularly released by damaged cells can trigger sterile inflammation through the 
engagement of the TLR4/MD2 receptor.  
In agreement with the emerging concept that DAMPs often potentiate their activity by binding to 
PAMPs, we demonstrate that the IFI16 proinflammatory activity is significantly enhanced when the 
protein is pre-incubated with subtoxic concentration of LPS and then added to the cells as pre-formed 
complex. Consistently, this effect is not observed when a truncated variant of IFI16 lacking the LPS-
binding domain is used. Despite the fact that IFI16 binds with similar affinity to different variants of 
LPS, we could only achieve a significant increase in proinflammatory cytokine release with the strong 
TLR4 agonists LPS-EB and LPS-F583. Of note, these LPS molecules when added alone to the cells, 
even at high doses, were only able to induce marginally the transcriptional activation of such 
cytokines. Interestingly, the LPS-F583-derived lipid A DPLA and MPLA, carrying respectively a di- 
and a monophosphorylated glucosamine dimer, both lacking the sugar inner core, display a 
remarkably different ability to enhance IFI16 activity. Although both molecules show the highest 
affinity for IFI16 in vitro, only DPLA partially retains the ability to potentiate IFI16 downstream 
signaling. Fittingly, IFI16 binding to Rhodobacter sphaeroides-derived LPS, which is known to 
antagonize the response to strong TLR4 activators in human and mouse monocytes (Anwar et al., 
2015), did not affect IFI16 proinflammatory activity. Interestingly, competition binding experiments 
in 786-O and THP-1 cells suggest that the affinity for TLR4 of either LPS-EB or LPS-RS is higher 
than that of IFI16. Indeed, when the cells are exposed to IFI16 and LPS-EB that were not pre-
complexed, the release of proinflammatory cytokines in the culture supernatants is far lower than that 
of cells exposed to pre-complexed IFI16/LPS-EB or IFI16 alone. Accordingly, the binding kinetics 
revealed by SPR analysis clearly indicated that LPS-EB has a much higher affinity for TLR4 and a 
very slow kinetics of dissociation when compared to the IFI16 protein alone. Conversely, the 
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IFI16/LPS-EB complex retains a higher affinity for TLR4 and is not displaced upon co-treatment 
with LPS-EB, as attested by the release of cytokines at levels similar to those observed in the 
supernatants of cells exposed to the complex alone. Likewise, IFI16/LPS-RS complex activity is not 
affected by the simultaneous addition of an equal amount of LPS-RS. In good agreement with the 
immunoprecipitation and competition assays, binding kinetics analysis by SPR reveals that LPS-EB, 
regardless of its overall higher affinity for TLR4/MD2, cannot compete with the IFI16/LPS-EB 
complex for binding to the receptor. Indeed, the IFI16/LPS-EB complex appears to be continuously 
engaged for TLR4 activation, as indicated by its faster association and dissociation rates. Thus, these 
data strongly suggest that in vivo i) the proinflammatory activity of IFI16 is enhanced upon its 
interaction with small amounts of circulating LPS, and ii) the IFI16/LPS-EB complex has a rapid 
stimulation turnover on the receptor, successfully competing with LPS-EB alone and leading to a 
massive inflammatory response (Fig 18). 
 
Fig 18. Proposed model depicting the inflammatory activities and binding kinetics to TLR4 of LPS and IFI16, 
alone or in combination. The relative inflammatory activities, from low to high, are reported in the upper part of the 
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scheme (orange arrow). The relative binding kinetics to TLR4 are reported in the lower part of the scheme (green 



















6. Conclusions and future perspectives 
Overall, our findings unveil a central role of extracellular IFI16 in triggering inflammation through 
its ability to bind the TLR4/MD2 complex, thereby triggering TLR4/MyD88/NF-B signaling. Given 
that IFI16 is able to form stable complexes with various LPS variants through interaction of its HINB 
domain with the lipid A moiety of LPS, we propose a new pathogenic mechanism regulated by 
extremely fine-tuned interactions between extracellular IFI16 and subtoxic doses of LPS, which are 
known to be present in various pathological settings other than gram-negative infections (Manco et 
al., 2010; Seki and Schnabl, 2012; Stoll et al., 2006). 
Our observation that the IFI16 PYRIN domain is responsible for binding to the TLR4/MD2 
receptor deserves a more comprehensive analysis of how these molecular entities are involved in this 
interaction. In addition, the molecular dynamic of the IFI16-LPS complex and the ensuing increased 
in TLR4 activation will be also further investigated. In the long term, we will identify novel 
therapeutic agents (e.g., small molecules, small peptides, antibodies) that inhibit the IFI16-mediated 
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Abstract
Damage-associated molecular patterns (DAMPs) are endogenous molecules activating the
immune system upon release from injured cells. Here we show that the IFI16 protein, once
freely released in the extracellular milieu of chronically inflamed tissues, can function as a
DAMP either alone or upon binding to lipopolysaccharide (LPS). Specifically, using pull-
down and saturation binding experiments, we show that IFI16 binds with high affinity to the
lipid A moiety of LPS. Remarkably, IFI16 DAMP activity is potentiated upon binding to sub-
toxic concentrations of strong TLR4-activating LPS variants, as judged by TLR4-MD2/
TIRAP/MyD88-dependent IL-6, IL-8 and TNF-α transcriptional activation and release in
stimulated monocytes and renal cells. Consistently, using co-immunoprecipitation (co-IP)
and surface plasmon resonance (SPR) approaches, we show that IFI16 is a specific TLR4-
ligand and that IFI16/LPS complexes display a faster stimulation turnover on TLR4 than
LPS alone. Altogether, our findings point to a novel pathomechanism of inflammation involv-
ing the formation of multiple complexes between extracellular IFI16 and subtoxic doses of
LPS variants, which then signal through TLR4.
Author summary
IFI16 is a nuclear protein involved in a variety of physiological processes, including cell
cycle regulation, tumor suppression, and virus sensing. Emerging evidence indicates that
IFI16 is released in the extracellular milieu under injury or stress conditions. Here we
show that extracellular IFI16 acts as a damage-associated molecular pattern (DAMP), trig-
gering inflammation through Toll-like receptor 4 (TLR4) activation. Furthermore, we
demonstrate that IFI16 activity is potentiated upon binding to subtoxic concentrations of
strong TLR4-activating lipopolysaccharide (LPS) variants, which are known to be present
PLOS PATHOGENS
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in various pathological settings other than gram-negative infections. Our study provides
new insights into the role of extracellular IFI16 during low-grade endotoxemia.
Introduction
In the absence of stress stimuli, expression of the nuclear IFI16 protein is restricted to hemato-
poietic cells, vascular endothelial cells and keratinocytes [1]. Since its discovery in the early
90s, IFI16 has been involved in a growing number of physiological processes, such as cell cycle
regulation, tumor suppression, apoptosis, DNA damage signaling, virus sensing and virus
restriction [2–5]. More recently, we and others have found that IFI16 can also be aberrantly
expressed in chronically inflamed tissues such as the intestinal epithelium of patients with
inflammatory bowel disease (IBD) [6,7] and the epidermis and inflammatory dermal infiltrates
of systemic lupus erythematosus (SLE) patients [8,9]. In addition, abnormal IFI16 expression
has been also detected in the skin of individuals affected by systemic sclerosis (SSc) [10] or pso-
riasis (Pso) [11–13], as well as in salivary epithelial cells and infiltrating lymphocytes of sub-
jects with Sjögren’s syndrome (SS) [14,15]. Noteworthy, serum circulating IFI16 protein and
its specific autoantibodies have also been reported in various autoimmune diseases, including
SSc, rheumatoid arthritis (RA), SLE, SS, psoriatic arthritis (PsA) and IBD [6,8,16–20]. Our
group and others have also reported IFI16 de-localization to the cytoplasm upon viral infection
or UVB exposure [8,21–23]. Importantly, under these conditions, IFI16 is eventually released
in the extracellular matrix where it acts as a damage-associated molecular pattern (DAMP),
inducing a proinflammatory phenotype [8,24]. However, the molecular mechanisms underly-
ing the extracellular DAMP activity of IFI16 have yet to be determined.
Lipopolysaccharide (LPS) is the main cause of gram-negative bacterial sepsis and among the
best-characterized pathogen-associated molecular patterns (PAMPs). It is made up of a lipid compo-
nent (lipid A), playing an essential role in promoting inflammation, and two sugar moieties subdi-
vided in a core polysaccharide and an O-polysaccharide of variable length [25]. Serum LPS is
recognized by the LPS binding protein (LBP), which then forms transient ternary complexes with
soluble or membrane-anchored CD14 (sCD14 or mCD14, respectively). Subsequently, CD14 disso-
ciates from LBP to extract monomeric LPS [26, 27] and through mCD14, LPS is finally presented to
the TLR4/MD2 complex, thereby leading to the activation of multiple signaling components, includ-
ing NF-κB and IRF3, which in turn transcriptionally activate proinflammatory cytokines [28].
Since we previously demonstrated that recombinant IFI16 can synergize with subtoxic con-
centrations of LPS to induce proinflammatory cytokine production in endothelial cells [24],
here we have explored the possibility that aberrant expression of IFI16 and its ensuing release
into the extracellular matrix may favor its interaction with exogenous molecules, such as LPS,
thereby triggering an inflammatory state also in other target cells.
In this study, we show for the first time that IFI16 binds with high affinity to the lipid A
moiety of LPS through its HINB domain. Moreover, we provide further evidence that IFI16
functions as a DAMP by triggering proinflammatory cytokine production in renal and mono-
cytic cell lines through the Toll-like receptor 4 (TLR4) signaling pathway, either alone or,
more potently, when complexed with strong TLR4-activating LPS variants.
Results
IFI16 binds to LPS of different bacterial origin and inflammatory activity
To investigate the occurrence of a direct association between IFI16 and LPS, we performed an
in vitro pull-down assay using biotin-labeled LPS from E. coli O111:B4 (biotin-LPS-EB) and
PLOS PATHOGENS IFI16 and LPS cooperate to activate TLR4
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008811 September 9, 2020 2 / 28
Funding: The investigators were supported by
grant 2015W729WH from the Italian Ministry for
University and Research (PRIN2015 to MDA),
grant CSTO168881 from the Compagnia di San
Paolo (CSP2016 to MDA), and grant from the
European Commission under the Horizon2020
program (H2020-MSCA-ITN-2015 to SL). This
study was partially funded by the AGING Project –
Department of Excellence– DIMET, University of
Eastern Piedmont. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
human recombinant IFI16 protein. As shown in Fig 1A, we could readily detect a highly repro-
ducible ~100-kDa band corresponding to biotin-LPS-bound IFI16. To rule out that this bind-
ing was due to bacterial contaminants, we next performed a pull-down assay using a
recombinant glutathione-S transferase (GST) protein prepared with the same procedure as
that employed to obtain recombinant IFI16. As shown in Fig 1B, we failed to isolate any GST-
containing band following incubation of GST with biotin-LPS-EB and streptavidin beads,
demonstrating the specificity of the IFI16/LPS interaction. Furthermore, saturation binding
experiments using IFI16-coated microtiter plates challenged with increasing amounts of bio-
tin-LPS-EB revealed biotin-labeled LPS bound to solid-phase IFI16 in a concentration-depen-
dent manner, reaching saturation at 100,000 ng/ml of biotin-LPS-EB (Fig 1C). When
recombinant GST or BSA were coated onto the microtiter plates, no binding occurred in the
presence of biotin-LPS-EB (Fig 1C). To assess binding specificity, we asked whether polymyxin
B (PMB), an LPS-sequestering agent able to bind to negatively charged phosphate groups of
lipid A [29], would disrupt IFI16/LPS interaction. As shown in Fig 1C, when PMB was pre-
incubated with biotin-LPS-EB and then added to the IFI16-coated wells, it completely pre-
vented IFI16 from binding to LPS. Next, IFI16/LPS-EB interaction was confirmed by surface
plasmon resonance (SPR) analysis flowing increasing amounts of LPS-EB over a CM5 IFI16-
coated chip. As shown in Fig 1D, LPS interacted with IFI16 in a concentration-dependent
manner, with a kinetic association constant (Ka) of 1.13
�104 1/Ms and a kinetic dissociation
constant (Kd) of 1.94
�10−3 1/s, respectively.
Altogether, these results indicate that IFI16 binds to LPS-EB with high affinity and that
such interaction is inhibited by PMB, presumably by masking the negatively charged groups of
the LPS lipid A moiety.
We next sought to determine whether IFI16 could bind to LPS in its natural setting, such as
the outer membrane of fixed gram-negative bacteria. To this end, a panel of gram-negative
bacteria, including a laboratory strain of E. coli and a clinical isolate of Klebsiella pneumoniae,
were assessed as solid phase antigens by whole cell ELISA. Gram-positive clinical isolates of
Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus pyogenes were used as
negative controls. As shown in Fig 1E, IFI16 strongly associated with the surface of both gram-
negative bacteria species. By contrast, no IFI16 binding could be detected when gram-positive
bacteria were used as solid phase antigens (Fig 1E). Thus, IFI16-LPS binding can also occur in
the natural setting where LPS is anchored to the bacterial outer membrane by its lipid A
moiety.
We next asked whether IFI16 would bind with the same affinity to LPS variants derived
from different gram-negative strains with highly variable structure and broad-spectrum activ-
ity. For this purpose, microtiter plates were coated with the following LPS variants: 1) the two
full TLR4 agonists E. coli O111:B4 (LPS-EB) and E. coli F583 (LPS-F583), with the latter har-
boring a similar lipid A moiety but a shorter polysaccharide chain length compared to that of
the O111:B4 strain; 2) the weak TLR4 agonist P. gingivalis (LPS-PG), carrying a mixture of di-,
mono- and de-phosphorylated penta- or tetra-acylated lipid A moieties; or 3) the TLR4 antag-
onist R. sphaeroides (LPS-RS), harboring a di-phosphorylated lipid A loaded with 3 long and 2
short acyl chains (Fig 1F). As shown in Fig 1G, IFI16 was able to bind to all the aforementioned
solid-phase LPS variants in a concentration-dependent manner, although with slightly differ-
ent kinetics. Specifically, we obtained similar KDs for the two E. coli LPS variants—i.e., 4.2 nM
and 4.3 nM for LPS-EB and LPS-F583, respectively—, while we observed slightly higher KDs
for LPS-PG and LPS-RS—i.e., 12.0 nM and 19.3 nM, respectively (Table 1). Consistently, treat-
ment of immobilized LPS molecules with PMB prior to the addition of IFI16 completely abol-
ished IFI16 binding. Thus, IFI16 binds to not only the canonical TLR4-activating LPS but also
variants characterized by weaker triggering activity.
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IFI16 binds to the lipid A moiety of LPS through its HINB domain
To identify which LPS moiety is involved in IFI16 binding, we performed saturation binding
experiments using two different variants of lipid A derived from the E. coli F583 strain, namely
diphosphorylated and monophosphorylated lipid A (DPLA and MPLA, respectively), along-
side a detoxified LPS molecule derived from the E. coli strain O111:B4 (detoxLPS) (Fig 2A).
The first two molecules lack the heteropolysaccharide outer chain and differ in the number of
phosphate groups, with MPLA being a weaker agonist than DPLA [30]. On the other hand, the
detoxLPS lipid A moiety is partially delipidated by alkaline hydrolysis, resulting in only four
primary acyl chains being directly esterified with the sugar moiety, in which the outer chain is
however preserved. DetoxLPS endotoxin levels are about 10,000 times lower than that of
parental LPS [31]. As shown in Fig 2B, IFI16 readily bound to both forms of lipid A in a con-
centration-dependent fashion. The KD values showed higher affinity for the lipid A moieties
(either form) in comparison with LPS-F583–0.9 nM and 1.2 nM, respectively, vs. 4.3 nM
(Table 1). Interestingly, the KD value for IFI16 binding to detoxLPS (55.6 nM) was the highest
among all LPS forms, indicating that the canonical acyl chain is required for IFI16 binding to
LPS. When lipid A was pre-treated with PMB, no signal was detected. Thus, LPS binds to
IFI16 through its lipid A moiety. To corroborate these data, a competition ELISA was per-
formed by immobilizing LPS from the E. coli strain O111:B4 (LPS-EB) onto the microtiter
Fig 1. IFI16 binds to LPS of different bacterial origin and inflammatory activity. Coomassie brilliant blue staining of pull-
down assays performed with 3 μg of recombinant IFI16 (A) or GST (B) in the presence or absence of biotin-labeled
lipopolysaccharide (LPS) from E. coli O111:B4 (biotin-LPS-EB). (C) Saturation binding experiments performed with 2 μg/ml
of IFI16 (red circles) and increasing amount of biotin-LPS-EB. Binding was detected by ELISA using HRP-conjugated
streptavidin. Optical density (OD) of samples was measured at 450 nm. An excess of recombinant GST (blue circles) or BSA
(green circles) and pre-treatment of biotin-LPS-EB with polymyxin B (PMB, empty circles) were used as negative controls.
Data are expressed as mean values ± SD of three independent experiments. (D) Surface plasmon resonance (SPR) analysis of
LPS-EB binding to immobilized IFI16. After immobilization of IFI16 on the CM5 sensor chip surface, increasing
concentration of LPS-EB (3.125–100 nM) diluted in running buffer were injected over immobilized IFI16. Data are
representative of three independent experiments. (E) Ex-vivo interaction analysis between increasing amount of recombinant
IFI16 and formalin-fixed gram-negative (E. coli and K. pneumonia; pink circles and pink squares, respectively) or gram-
positive (S. aureus, S. epidermidis, S. pyogenes; blue circles, squares and triangles, respectively) bacteria. Data are expressed as
mean values ± SD of three independent experiments. (F) Lipid A structures of LPS derived from E. coli O111:B4 or F583 LPS
(LPS-EB and LPS-F583, respectively; strong TLR4 agonists), P. gingivalis (LPS-PG; weak TLR4 agonist) and R. sphaeroides
(LPS-RS, TLR4 antagonist). For LPS-PG, which harbors a mixture of di-, mono- and de-phosphorylated penta- or tetra-
acylated lipid A moieties, a single isoform is represented for simplicity. PS-outer chain = polysaccharide outer chain. (G)
Saturation binding experiments with increasing amount of recombinant IFI16 (8 to 12,288 ng/ml) and 10 μg/ml of LPS-EB
(red line), LPS-F583 (green line), LPS-PG (blue line) or LPS-RS (purple line). Anti-IFI16 antibodies against the N-terminus
of the protein and HRP-labelled anti-rabbit IgG were added as primary and secondary antibody, respectively, and binding
was detected by ELISA at 450 nm. Data are expressed as mean values ± SD of three independent experiments.
https://doi.org/10.1371/journal.ppat.1008811.g001
Table 1. Full-length IFI16 and IFI16 domains binding affinities to LPS.
LPS variant Equilibrium dissociation constant (KD), nM
IFI16 PYRIN HINA HINB
LPS E. coli O111:B4 (LPS-EB) 4.2 116.5 85.3 3.3
LPS E. coli F583 (LPS-F583) 4.3 - - -
LPS P. gingivalis (LPS-PG) 12.0 46.9 84.0 1.6
LPS R. sphaeroides (LPS-RS) 19.3 - - -
DPLA E. coli F583 (DPLA) 0.9 47.5 67.7 2.8
MPLA E. coli F583 (MPLA) 1.2 47.2 94.1 2.7
Detoxified LPS E. coli O111:B4 (detoxLPS) > 20 - - -
KD, equilibrium dissociation constant
https://doi.org/10.1371/journal.ppat.1008811.t001
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plates followed by the addition of a mixture of a constant amount of IFI16 and increasing con-
centrations of LPS-EB, MPLA or detoxLPS, in this case used as competitors. As expected, addi-
tion of LPS-EB reduced IFI16 binding to immobilized LPS in a concentration-dependent
manner (Fig 2C, white bars). Interestingly, a concentration of 5 μg/ml of MPLA was sufficient
enough to achieve a much stronger reduction in IFI16 binding to LPS compared to a similar
dose of LPS-EB (Fig 2C, grey bars). Binding inhibition was further enhanced at higher concen-
trations of MPLA, but the difference between the two variants was less evident. By contrast,
detoxLPS did not interfere with the binding of IFI16 to the canonical agonist LPS, even at the
highest concentrations used (25 μg/ml: LPS-EB vs. detoxLPS, P = 0.0059; MPLA vs. detoxLPS,
P< 0.0004; LPS-EB vs. MPLA, ns; unpaired t-test) (Fig 2C, black bars). Taken together, these
findings indicate that lipid A is the LPS moiety involved in the binding to IFI16 and that the
heteropolysaccharide outer chain, absent in MPLA, might constitute a steric hindrance for
such interaction.
To identify the domain of IFI16 mediating binding to LPS, an in vitro pull-down assay was
performed using three distinct recombinant domains of IFI16 spanning either the N-terminal
portion containing the pyrin domain (PYRIN) or each of the 200 amino acid-long HIN
domains (namely HINA or HINB) (Fig 2D). As shown in Fig 2E, a signal at ~35 kDa was only
detected when the HINB fragment was incubated with biotin-LPS-EB bound to streptavidin
beads (lane 9), while neither the PYRIN nor the HINA fragment was co-precipitated in the
presence of biotinylated LPS (lanes 3 and 6). To corroborate these data, an in vitro pull-down
assay was performed using a truncated variant of IFI16 lacking the HINB domain (IFI16Δ-
HINB) (S1A Fig). As expected, no binding was observed when IFI16ΔHINB was incubated
with biotin-LPS-EB and streptavidin beads (S1B Fig, lane 2), confirming that the HINB is
required for LPS binding. To further support a role of the HINB domain in mediating the
binding of IFI16 to LPS, we performed saturation binding experiments using increasing con-
centrations of the three IFI16 domains (i.e., PYRIN, HINA, and HINB) with fixed amounts of
different interactors. As shown in Fig 2F (blue lines), the HINB domain was able to bind to
both LPS variants, displaying either strong or weak TLR4 agonist activity, as well as to lipid A.
The binding was not affected by the origin of bacterial LPS or by the number of phosphate
groups, and displayed KD values in a similar range to that obtained with the full-length recom-
binant IFI16 protein (Table 1). Conversely, the PYRIN (orange lines) and HINA (purple lines)
Fig 2. FI16 binds to the lipid A moiety of LPS through its HINB domain. (A) Structures of di- or mono-
phosphorylated lipid A from E. coli F583 (DPLA and MPLA, respectively) and detoxified LPS (detox-LPS) derived
from E. coli O111:B4. PS-outer chain = polysaccharide outer chain. (B) Saturation binding experiments with
increasing amount of recombinant IFI16 (from 8 to 12,288 ng/ml) and 10 μg/ml of MPLA (green line), DPLA (red
line) or detox-LPS (purple line). Binding was detected by ELISA as described in the legend to Fig 1G. Data are
expressed as mean values ± SD of three different experiments. (C) Competition ELISA assay for LPS-EB binding to
IFI16 with increasing amount of LPS-EB, MPLA or detox-LPS as competitors. Briefly, microtiter plates were coated
with 1 μg/ml LPS-EB, then 2 μg/ml of IFI16 were added to the wells in the presence of increasing concentration (5 to
25 μg/ml) of competitor. Binding was detected by ELISA as described in the legend to Fig 1F. Data are expressed as
mean values ± SD of three independent experiments (���P<0.001, ��P<0.01, Student’s t test). (D) Domain
organization of the IFI16 protein. The numbers represent the amino acid positions based on NCBI Reference Sequence
NP_005522. From the N- to the C-terminal (left to right), IFI16 comprises a pyrin domain involved in protein-protein
interaction, and two hematopoietic interferon-inducible nuclear protein with 200-amino-acid repeats (HINA and
HINB) domains, which are a hallmark of the absent in melanoma 2-like receptors (ALRs). S/T/P = serine/threonine/
proline-rich repeats, which are regulated by alternative mRNA splicing. (E) Coomassie brilliant blue staining of pull-
down assays performed with 3 μg of recombinant PYRIN, HINA, and HINB domains, in presence or absence of
biotin-labeled LPS from E. coli O111:B4 (biotin-LPS-EB). (F) Saturation binding experiments performed by using
increasing amount (8 to 4,096 ng/ml) of recombinant PYRIN, HINA or HINB domains (orange, purple and blue lines,
respectively) and 10 μg/ml of LPS-EB, LPS-PG, MPLA or DPLA. Anti-IFI16 antibodies against the N- or C-terminus
of the protein and HRP-labeled anti-rabbit IgG were added as primary and secondary antibody, respectively, and
binding detected in ELISA at 450 nm. Data are expressed as mean values ± SD of three independent experiments.
https://doi.org/10.1371/journal.ppat.1008811.g002
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domains displayed very low affinity for the immobilized molecules when compared to HINB,
with KD values indicative of unspecific binding (Table 1). Thus, the HINB domain displays the
highest affinity for LPS, indicating that HINB may play a major role in the interaction between
IFI16 and LPS.
Only potent TLR4-activating endotoxins can potentiate the
proinflammatory activity of IFI16
The results so far obtained prompted us to investigate whether IFI16 binding to the strong
agonist variant LPS-EB would modulate IFI16-mediated transcriptional activation of proin-
flammatory cytokines in vitro. For these experiments, in addition to the standard human
monocytic cell line THP-1, we chose as a model the renal tubular carcinoma cell line 786-O.
We first assessed protein expression levels of the main components of the LPS recognition
complex (i.e., TLR4, MD2, MyD88 and CD14) by Western blotting and/or flow cytometry (S2
Fig). While TLR4 and MD2 were expressed at similar levels in both cell lines, CD14 expression
was 4-fold lower in THP-1 vs. 786-O cells, as judged by FACS analysis (S2B Fig), in good
agreement with a previous report [32]. The expression of the TLR4 canonical adaptor MyD88
was similar in both cell lines (S2A Fig).
Next, cells were stimulated with full-length IFI16 or the IFI16ΔHINB variant, alone or pre-
incubated with LPS-EB, and then total RNA was extracted to assess mRNA levels of a panel of
proinflammatory cytokines (Fig 3A). Consistent with IFI16 acting as a DAMP, IL-6, IL-8 and
tumor necrosis factor-α (TNF-α) mRNA levels were strongly upregulated in cells treated with
IFI16 alone when compared to mock- or LPS-treated cells in the presence of either low or high
LPS concentration. Interestingly, we detected a further increase in mRNA expression levels of
the aforementioned genes in cells treated with the IFI16/LPS-EB complex compared to IFI16
alone—i.e., 1.8- and 1.6-fold induction for IL-6; 1.7- and 1.3-fold induction for IL-8; and 2.1-
and 1.6-fold induction for TNF-α in 786-O and THP-1 cells, respectively. Likewise, IL-1β gene
expression levels were also significantly induced by IFI16 alone or IFI16/LPS-EB complex
treatment of THP-1 cells—i.e., 72- and 83-fold induction, respectively—and, albeit to a lower
extent, 786-O cells—i.e., 13- and 27-fold induction, respectively. When IFI16ΔHINB alone or
pre-incubated with LPS-EB was used to stimulate the cells, the degree of cytokine induction
was similar to that observed with the full-length protein, while it was not enhanced following
pre-incubation with LPS-EB.
Altogether, these findings further strengthen the notion that the HINB moiety is necessary
for the formation of the functional IFI16/LPS complex.
Consistent with the mRNA data, the amounts of IL-6, IL-8 and TNF-α secreted into the cul-
ture supernatants were significantly higher in cells treated with the IFI16/LPS-EB complex
than those of cells treated with IFI16 alone, while they did not vary upon pre-incubation with
LPS-EB in the case of the IFI16ΔHINB variant (Fig 3B). In contrast, neither IFI16 nor IFI16Δ-
HINB per se or after forming a complex with LPS induced IL-1β release in both cell lines, indi-
cating lack of inflammasome-mediated IL-1β processing at 24 h post-treatment.
Next, we asked whether the LPS derivatives DPLA and MPLA or the TLR4 antagonist
LPS-RS would be equally able to modulate the biological activity of IFI16. The full agonist
LPS-F583, from which DPLA and MPLA were derived, was included as positive control (full
TLR4 activator). Cells were treated with the aforementioned compounds, alone or pre-com-
plexed with IFI16 protein, and then total RNA and supernatants were collected to assess the
mRNA expression and cytokine production profiles of IL-6, IL-8 and TNF-α. As expected,
cells treated with the IFI16/LPS-F583 displayed a similar transcriptional activation pattern to
that previously observed in IFI16/LPS-EB-treated cells (Fig 4A). On the other hand, when cells
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were treated with IFI16 complexed with LPS-RS, MPLA or DPLA, we failed to observe any
transcriptional enhancement in comparison with IFI16 alone. A similar pattern was found
when the same cytokines were measured in the culture supernatants by ELISA (Fig 4B),
although a significant increase in IFI16-induced secretion of IL-6 and IL-8 was only observed
when cells were treated with the IFI16-DPLA complex—i.e., 1.4-fold induction for IL-6 in
THP-1 cells, 1.3- and 1.8-fold induction for IL-8 in 786-O and THP-1, respectively.
Fig 3. IFI16 proinflammatory activity is potentiated by the strong TLR4 activator LPS-EB. (A) qRT-PCR analysis of IL-6, IL-8, TNF-α
and IL-1β mRNA expression levels in 786-O or THP-1 cells stimulated for 24 h with IFI16 (25 μg/ml), IFI16ΔHINB (25 μg/ml), LPS from E.
coli O111:B4 (LPS-EB, 10 ng/ml or 1 μg/ml), IFI16/LPS-EB complex (preincubated O/N at 4˚C), IFI16ΔHINB/LPS-EB (preincubated O/N
at 4˚C), or left untreated (mock). Values are normalized to GAPDH mRNA and plotted as fold induction over mock-treated cells. qRT-PCR
data are presented as mean values of biological triplicates. Error bars indicate SD (�P< 0.05, ��P< 0.01, ���P< 0.001; two-way ANOVA
followed by Dunnett’s test). (B) Protein concentration of IL-6, IL-8 and TNF-α evaluated by ELISA in supernatants derived from 786-O or
THP-1 cells stimulated for 24 h as described in A. Data are expressed as mean values ± SD of three independent experiments (�P< 0.05,
��P< 0.01, ���P< 0.001; two-way ANOVA followed by Dunnett’s test).
https://doi.org/10.1371/journal.ppat.1008811.g003
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Collectively, these data indicate that the proinflammatory activity of full-length IFI16 is
potentiated when this protein is complexed with potent TLR4-activating LPS variants via the
HINB moiety, while it is not affected when it forms a complex with the TLR4 antagonist
LPS-RS or the weak agonists MPLA and DPLA.
IFI16 exerts its proinflammatory activity in a TLR4/MyD88-dependent
fashion
Since we had previously implicated TLR4 signaling in IFI16-mediated cytokine release in
endothelial cells [24], we sought to determine whether ablation of the TLR4/MD2 complex
would affect IFI16/LPS proinflammatory activity. To this end, we performed gene silencing of
TLR4 and MD2 genes in both 786-O and THP-1 cells, achieving complete knockdown of both
genes, as judged by immunoblotting and flow cytometric analysis (S3A–S3C Fig). As shown in
S4 Fig, the transcriptional activation of IL-6, IL-8 and TNF-α genes (panels A and B) as well as
Fig 4. Weak TLR4-activating LPS variants and the TLR4 antagonist LPS-RS do not potentiate IFI16
proinflammatory activity. (A) qRT-PCR analysis of IL-6, IL-8 and TNF-α mRNA expression levels in 786-O or THP-
1 cells stimulated for 24 h with or without IFI16 (25 μg/ml), LPS from E. coli F583 (LPS-F583, 10 ng/ml) or LPS from
R. sphaeroides (LPS-RS, 10 ng/ml), MPLA (10 ng/ml), DPLA (10 ng/ml) or in the presence of one of the following
complexes: IFI16/LPS-F583, IFI16/LPS-RS, IFI16/MPLA or IFI16/DPLA. Values are normalized to GAPDH mRNA
and plotted as fold induction over mock-treated cells. qRT-PCR data are presented as mean values of biological
triplicates. Error bars indicate SD, and the P values refer to comparisons between IFI16 vs. IFI16/LPS or IFI16/lipid A
complex-treated cells (�P< 0.05, ��P< 0.01, ���P< 0.001; two-way ANOVA followed by Dunnett’s test). (B) Protein
concentration of IL-6, IL-8 and TNF-α evaluated by ELISA in supernatants derived from 786-O or THP-1 cells
stimulated for 24 h as described in the legend to panel A. Data are expressed as mean values ± SD of three independent
experiments (�P< 0.05, ��P< 0.01, ���P< 0.001; ns, not significant; two-way ANOVA followed by Dunnett’s test).
The P values are relative to comparisons between IFI16- and IFI16/LPS- or IFI16/lipid A-treated cells.
https://doi.org/10.1371/journal.ppat.1008811.g004
PLOS PATHOGENS IFI16 and LPS cooperate to activate TLR4
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008811 September 9, 2020 10 / 28
the release of the same cytokines (Fig 5A, B) in the culture supernatants upon exposure to both
IFI16 or IFI16/LPS-EB was almost completely abolished in siTLR4- and siMD2-silenced cells
when compared to siRNA control (siCTRL)-transfected cells. Similar results were obtained in
both 786-O and THP-1 cells, indicating that IFI16 signaling through the TLR4-MD2 complex
is not cell type-specific.
Upon LPS stimulation, TLR4 induces two independent signaling pathways regulated by
either the TIRAP/MyD88 or TRAM/TRIF pair of adaptors, which promote the production of
Fig 5. IFI16 exerts its proinflammatory activity in a TLR4/MyD88-dependent fashion. (A-C) Protein
concentration of IL-6, IL-8 and TNF-α measured by ELISA in supernatants derived from 786-O or THP-1 cells
transfected for 48 h with scramble control (siCTRL), or siRNAs against TLR4 (siTLR4, A), MD2 (siMD2, B) or MyD88
(siMyD88, C). Cells were then stimulated for 24 h with IFI16 (25 μg/ml), LPS from E. coli O111:B4 (LPS-EB, 10 ng/ml)
or IFI16/LPS-EB complex (preincubated O/N at 4˚C), or left untreated (mock). Data are expressed as mean
values ± SD of three independent experiments (�P< 0.05, ��P< 0.01, ���P< 0.001, ns: not significant; unpaired
Student’s t-test for comparison of silenced cells vs. their relative control counterpart). (D) Schematic representation of
the probe containing the NF-κB binding site (highlighted in grey). (E) 786-O cells or THP-1 cells were stimulated with
IFI16 (25 μg/ml), LPS from E. coli O111:B4 (LPS-EB, 10 ng/ml) or IFI16/LPS-EB complex (preincubated O/N at 4˚C),
or left untreated (mock). After 2 h, the cells were lysed and the nuclear fraction was analyzed for NF-κB binding
activity using the Universal EZ-TFA transcription factor assay colorimetric kit and the probe described in D. Data are
expressed as mean values ± SD of three independent experiments (�P< 0.05, ��P< 0.01, ���P< 0.001; two-way
ANOVA followed by Dunnett’s test).
https://doi.org/10.1371/journal.ppat.1008811.g005
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proinflammatory cytokines and type I interferons (IFN-I), respectively [33,34]. As IFN-β
could never be detected in IFI16- or IFI16/LPS-stimulated cells, we assumed that the TRAM-
TRIF pathway would not play a role in our model. To address a potential role of the TIRAP-
MyD88 complex, we performed siRNA-mediated knockdown of MyD88 in both 786-O and
THP-1 cells (S3D Fig). In MyD88-silenced cells treated with IFI16 alone or IFI16/LPS-EB,
transcription of IL-6, IL-8 and TNF-α genes (S4C Fig) and release of the corresponding cyto-
kines (Fig 5C) were dramatically reduced in comparison with siCTRL-transfected cells, indi-
cating that IFI16 or the IFI16/LPS complex signals through the TIRAP-MyD88 axis. Fittingly,
ELISA-based transcription factor binding assay, performed using a probe containing the NF-
κB binding site (Fig 5D), showed NF-κB binding activity to be significantly increased in cells
challenged with IFI16 alone or pre-complexed with LPS-EB in comparison with untreated
cells—i.e., 2.2- and 3.9-fold induction in 786-O cells; 2.4- and 2.9-fold induction in THP-1
cells, respectively (Fig 5E). Overall, these results demonstrate that IFI16-mediated proinflam-
matory cytokine production requires the TLR4-MD2/TIRAP-MyD88 signaling pathway,
which then promotes NF-κB nuclear binding activity to target DNA.
Finally, to circumvent potential issues of structural or functional differences between mam-
malian or bacterial expressed IFI16, we used wild-type and IFI16-knockout (IFI16-/-) human
osteosarcoma U2OS cells as a source of endogenous IFI16 released under stress stimuli. As
shown in Fig 6A, and consistent with our previous report [8], UVB treatment (800 Jm-2 for
16h) led to massive release of IFI16 in the culture supernatants of U2OS cells that, as expected,
did not occur in their IFI16-/- counterparts, thus serving as IFI16-depleted supernatant. The
resulting conditioned media were preincubated with or without LPS-EB or LPS-RS and then
added to THP-1 cells. After 24 h, the supernatants of the THP-1 cultures were harvested and
assessed for cytokine expression by ELISA. Consistent with the results obtained with recombi-
nant IFI16, exposure of THP-1 cells to conditioned medium from UVB-treated U2OS cells sig-
nificantly stimulated the release of IL-6, IL-8 and TNF-α by THP-1 cells when compared to
mock-treated cells—i.e., 20.9-fold higher for IL-6; 83-fold for IL-8; and 33.4-fold for TNF-α
(Fig 6B). When THP-1 cells were pre-treated with anti-TLR4 antibodies, the stimulatory activ-
ity of the conditioned medium form UVB-treated U2OS cells dropped significantly. Notably,
cytokine release was significantly lower in THP-1 cells treated with conditioned medium from
UVB-treated U2OS-IFI16-/- cells when compared to their UVB-treated normal counterparts—
i.e., 2.8-fold lower for IL-6; 2.7-fold for IL-8; and 2.6-fold for TNF-α—, indicating that the
effects observed were specifically due to the secretion of IFI16 protein. Consistent with the
data obtained with the recombinant protein, cytokine release was enhanced when the condi-
tioned media were preincubated with LPS-EB and, to a higher extent, with the conditioned
medium of UVB-treated U2OS cells when compared to that of UVB-treated U2OS-IFI16-/-
cells. As expected, this enhancement was not observed when LPS-RS was used.
IFI16 binds to TLR4 in vivo and in vitro
We next sought to determine whether IFI16 could also bind to the TLR4/MD2 complex in
vivo. To this end, co-immunoprecipitation assays were performed where TLR4 and interacting
partners were immunoprecipitated using an anti-TLR4 antibody pre-adsorbed on protein G
beads. The resulting immune complexes were then analyzed by SDS-PAGE followed by immu-
noblotting for TLR4, MD2, and IFI16. As shown in Fig 7A, IFI16 co-immunoprecipitated with
TLR4/MD2 receptor when total extracts from cells treated with either IFI16 alone or IFI16/
LPS-EB complex were used (lane 2 and 4, respectively). The specificity of this interaction was
attested by the absence of co-immunoprecipitated IFI16 in extracts from cells untreated or
treated with LPS-EB alone (lane 1 and 3, respectively). To ensure that residual DNA potentially
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present in the protein extracts would not affect Co-IPs, whole-cell extracts were treated with
DNase and then subjected to Co-IP. As shown in Fig 7A (lane 5 and 6, respectively), the inter-
action between IFI16 or IFI16/LPS and TLR4 was maintained also in protein extracts obtained
from DNase-treated cells, indicating that the interaction between these molecules is not medi-
ated by DNA binding.
The specificity of the interaction between IFI16 and TLR4 was then evaluated by surface
plasmon resonance (SPR). Briefly, recombinant TLR4 was directly immobilized on a CM5 sen-
sor chip by amine coupling and then probed with increasing concentration of recombinant
IFI16—from 31.25 nM to 1 μM. As shown in Fig 7B, the resulting SPR sensorgrams revealed
significant binding between TLR4 and IFI16 with an equilibrium dissociation constant (KD) of
0.13 μM and a kinetic profile typical of dynamically interacting partners, with the dissociation
rate being compatible with a rapid stimulation turnover of the ligand (i.e., IFI16) on the TLR4
receptor. Thus, taken together these results indicate that the proinflammatory activity of IFI16,
either alone or pre-complexed with LPS, is mediated by the TLR4/MD2/MyD88/NF-κB signal-
ing pathways and requires a direct interaction between IFI16 and TLR4.
The IFI16/LPS complex proinflammatory activity is not affected by the
presence of free LPS
To gain more insights into the biological relevance of the IFI16/LPS complex vs. LPS, we sought
to determine the proinflammatory activity of IFI16 or IFI16/LPS complex in the presence or
absence of equal amounts of LPS simultaneously added to the cells. For this purpose, 786-O and
THP-1 cells were stimulated with an array of different combinations as indicated in Fig 8. When
IFI16 and LPS-EB were simultaneously added to the cells, without any pre-incubation step, induc-
tion of IL-6, IL-8 and TNF-α at both the mRNA and protein levels (Fig 8A and 8B, respectively)
was comparable to that observed using LPS-EB alone, indicating that the affinity of IFI16 for the
TLR4/MD2 receptor is lower than that of LPS. In contrast, when LPS-EB was simultaneously
added to the cells together with the pre-formed IFI16/LPS-EB complex, induction of IL-6, IL-8
and TNF-α at both the mRNA and protein levels was comparable or even higher than that
observed in cells stimulated with the IFI16/LPS-EB complex alone, suggesting that the affinity of
the IFI16/LPS-EB complex for the TLR4 receptor is stronger than that of LPS-EB alone. Similar
results were obtained when LPS-RS, a TLR4 antagonist, was used with the same combination
treatment. Again, IFI16/LPS-RS complex activity, as measured by the induction of IL-6, IL-8 and
TNF-α, was not affected by simultaneous addition of equal amounts of LPS-RS. Taken together,
these findings clearly show that once IFI16 is complexed with LPS its proinflammatory activity is
not affected by the simultaneous addition of LPS, regardless of its bacterial origin.
To better clarify the dynamics of interaction between IFI16/LPS-EB complex and TLR4/
MD2 receptor, we performed further SPR analyses by means of a CM5 sensor chip coated with
Fig 6. Endogenous IFI16 is released by UVB-exposed U2OS cells and triggers proinflammatory cytokines
production in a TLR4-dependent fashion. (A) Western blot analysis of IFI16 in culture supernatants and total cell
extracts of UVB-exposed (0 or 800 Jm-2) U2OS or U2OS-IFI16-/- cells at 16 h after treatment. β-actin cellular
expression was used for protein loading control. Data are representative of three independent experiments with similar
results. (B) Protein concentration of IL-6, IL-8 and TNF-α evaluated by ELISA in supernatants derived from THP-1
cells stimulated for 24 h in the presence or absence of anti-TLR4 neutralizing antibodies (10 μg/ml) using conditioned
medium from UVB-exposed (0 or 800 Jm-2) U2OS and U2OS-IFI16-/- cells, or complete medium (mock),
preincubated (O/N at 4˚C), or not, with LPS from E. coli O111:B4 (LPS-EB, 10 ng/ml), or LPS from R. sphaeroides
(LPS-RS, 10 ng/ml). Values were normalized to the initial protein concentration of the analyzed cytokines in the
supernatants used for the treatment. Data are expressed as mean values ± SD of three independent experiments. The P
values refer to comparison in each group with cells treated only with the medium without any addiction (white bar and
black border; �P< 0.05, ��P< 0.01, ���P< 0.001; two-way ANOVA followed by Dunnett’s test).
https://doi.org/10.1371/journal.ppat.1008811.g006
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recombinant TLR4/MD2. As shown in Table 2, the SPR-based studies demonstrated that the
three receptor partners (i.e., IFI16, LPS-EB and the IFI16/LPS-EB complex) had association
rate (Ka) values in the same range, with IFI16/LPS-EB showing a 3- and 2-fold faster associa-
tion compared to IFI16 or LPS-EB alone, respectively. Interestingly, in agreement with our
Fig 7. IFI16 binds to TLR4 in vitro and in vivo. (A) 786-O cells were stimulated for 1 h in the presence or absence of
the indicated concentrations of IFI16, LPS from E. coli O111:B4 (LPS-EB), or IFI16/LPS-EB complex. Total cell
extracts, untreated or DNase I-treated, were subjected to immunoprecipitation using a TLR4 monoclonal antibody.
Immunoprecipitates and whole-cell lysates were analyzed by immunoblotting with anti-IFI16, anti-TLR4 or anti-MD2
antibodies. β-actin protein expression was used for protein loading control. Data are representative of three
independent experiments with similar results. (B) Surface plasmon resonance (SPR) analyses of IFI16 binding to
immobilized TLR4. After immobilization of TLR4 on the CM5 sensor chip surface, increasing concentration of IFI16
(31.25–1,000 nM) diluted in running buffer were injected over immobilized TLR4. IFI16 binds to TLR4 with an
equilibrium dissociation constant (KD) of 0.13 μM. Data are representative of three independent experiments.
https://doi.org/10.1371/journal.ppat.1008811.g007
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previous findings, IFI16 interacted with the TLR4/MD2 complex in a concentration-depen-
dent manner with a KD of 0.68 μM, as calculated by the evaluation of the sensorgrams in Fig
8C. Moreover, LPS-EB alone revealed a much higher affinity, with a KD of 0.15 nM. In con-
trast, IFI16/LPS-EB complex bound to TLR4/MD2 with 6-fold lower affinity (KD = 4.01 μM)
Fig 8. The IFI16/LPS complex proinflammatory activity is not affected by the presence of free LPS. (A) qRT-PCR
analysis of IL-6, IL-8, TNF-α and mRNA expression levels in 786-O or THP-1 cells stimulated for 24 h with IFI16 (25
μg/ml), LPS from E. coli O111:B4 (LPS-EB, 10 ng/ml), IFI16/LPS-EB complex, IFI16 + LPS-EB (not complexed),
IFI16/LPS-EB complex + LPS-EB (10 ng/ml), LPS from Rhodobacter sphaeroides (LPS-RS, 10 ng/ml), IFI16/LPS-RS
complex, IFI16 + LPS-RS (not complexed), IFI16/LPS-RS complex + LPS-RS (10 ng/ml), or left untreated (mock).
Values were normalized to GAPDH mRNA and plotted as fold induction over mock-treated cells. The P values refer to
comparisons with IFI16-treated cells (�P< 0.05, ��P< 0.01, ���P< 0.001; one-way ANOVA followed by Dunnett’s
test). (B) Protein concentration of IL-6, IL-8 and TNF-α was measured by ELISA in supernatants derived from 786-O
or THP-1 cells stimulated for 24 h as described in A. Data are expressed as mean values ± SD of three independent
experiments. The P values refer to comparisons with IFI16-treated cells (�P< 0.05, ��P< 0.01, ���P< 0.001; one-way
ANOVA followed by Dunnett’s test). (C) Surface plasmon resonance (SPR) analyses of IFI16, LPS-EB and IFI16/
LPS-EB complex binding to immobilized TLR4/MD2 receptor. After immobilization of recombinant TLR4/MD2 on
the CM5 sensor chip surface, increasing concentration of the different analytes—31.25–1000 nM for IFI16, 3.125–
100 μM for LPS-EB, 31.25–1000 nM for IFI16/LPS-EB complex—diluted in running buffer were injected over
immobilized TLR4/MD2. IFI16, LPS-EB, and IFI16/LPS-EB bind to TLR4/MD2 with an equilibrium dissociation
constant (KD) of 0.68 μM, 0.15 nM, and 4.01 μM, respectively. Data are representative of three independent
experiments.
https://doi.org/10.1371/journal.ppat.1008811.g008
Table 2. Binding kinetics of IFI16, LPS-EB and IFI16/LPS-EB to TLR4/MD2 receptor.
Ka (1/Ms) Kd (1/s) KD (M) Rmax (RU) Chi
2 (RU)
IFI16 9.07�103 6.14�10−3 6.77�10−7 26.09 1.83
LPS-EB 6.84�103 1.00�10−6 1.47�10−10 745.00 14.30
IFI16/LPS-EB 3.57�103 1.43�10−2 4.01�10−6 90.30 6.89
Ka, association rate constant; M, molarity; s, seconds; Kd, dissociation rate constant; KD, equilibrium dissociation constant; Rmax, maximum response; RU, response
units; Chi2, average squared residual.
https://doi.org/10.1371/journal.ppat.1008811.t002
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when compared to IFI16 alone. The lower KD displayed by LPS-EB was mainly due to the con-
tribution of a lower dissociation rate constant (Kd = 1.00
�10−6 s-1), indicating that the kinetics
of LPS-EB dissociation from the receptor is very slow. Interestingly, the sensorgrams demon-
strated a much higher dissociation rate for both free IFI16 (Kd = 6.14
�10−3 s−1) and the IFI16/
LPS-EB complex (Kd = 1.43
�10−2 s−1) in comparison with LPS-EB alone, indicating that bind-
ings involving IFI16 are much less stable once formed. In agreement with the cytokine release,
the aforementioned results indicate that, when added separately, LPS-EB binds to TLR4/MD2
more rapidly than IFI16 alone. In this setting, LPS-EB per se is able to trigger a weak inflamma-
tory response highly likely due to its slow dissociation from the receptor, which in turn delays
the optimal turnover of the receptor. In contrast, IFI16/LPS-EB complex binds to TLR4 more
rapidly than LPS-EB simultaneously added to the cells, and it is released much more rapidly.
Discussion
We previously reported that extracellular IFI16 promotes IL-6 and IL-8 production in endo-
thelial cells, and that such proinflammatory activity is amplified in the presence of subtoxic
concentrations of LPS-EB, a full activator of the TLR4 signaling pathway [24]. Here, we expand
on those observations by showing that, in renal and monocytic cell lines, IFI16 either alone or
in complex with LPS binds to TLR4, thereby triggering a proinflammatory response through
the TLR4/MD2/MyD88 signaling pathway. Specifically, by means of in vitro pull-down assays
and saturation binding experiments, we provide the first evidence that the HINB domain of
IFI16 mediates complex formation with LPS-EB or LPS-F583, two E. coli-derived variants of
LPS capable of acting as strong TLR4 agonists [35,36]. This interaction follows a prototypical
associative binding, with increasing rate of binding up to the plateau phase following addition
of increasing amounts of the analytes. Furthermore, this binding is not dependent on the poly-
saccharide outer chain length as both LPS-EB and LPS-F583 display similar binding affinity
for IFI16—the LPS-F583 variant is in fact characterized by the presence of a shorter polysac-
charide chain compared to that of LPS-EB [37]. In addition, we show that both LPS-PG, a
weak TLR4 agonist [38], and LPS-RS, a TLR4 antagonist [39]—these molecules display fewer
acyl chains in their lipid A moieties compared to LPS-EB—, bind to IFI16 with similar affini-
ties, albeit slightly lower than those of LPS-EB and LPS-F583. Finally, using the E. coli
F583-derived DPLA and MPLA lipid A variants [37,40], we demonstrate that lipid A is the
LPS moiety interacting with IFI16-HINB, affording the highest affinity for LPS. Accordingly,
the detoxified variant of LPS-EB, containing a lipid A moiety partially delipidated by alkaline
hydrolysis, binds weakly to IFI16. The observation that the HINB domain of IFI16 has a much
higher affinity for lipid A than that of the HINA domain, despite both molecules being highly
similar in terms of primary sequence and overall structure topology, is only partially unex-
pected. Indeed, these two IFI16 domains have already been shown to have distinct modes of
binding to another paradigmatic PAMP—i.e., viral DNA—most likely due to their different
folding structures [41,42].
In recent years, mounting evidence has shown how TLRs, besides sensing exogenous
microbial components, are also capable of recognizing endogenous material released during
cellular injury, thereby promoting a non-microbial-induced inflammatory state known as ster-
ile inflammation, which if not resolved can lead to severe acute and chronic inflammatory con-
ditions [43–45]. Here, we propose that IFI16 might represent a novel trigger of sterile
inflammation acting through the TLR4 signaling pathway. In particular, we show that expo-
sure to recombinant IFI16 can induce IL-6, IL-8 and TNF-α transcriptional activation and
release of these cytokines into the culture supernatants. This induction is strictly dependent on
the presence of the TLR4/MD2 receptor complex and the MyD88 adaptor. By contrast, the
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membrane-associated CD14 receptor seems to be only marginally involved in this signaling
pathway given that undifferentiated THP-1 cells, displaying low levels of CD14 expression,
and 786-O cells, expressing high levels of CD14, show similar cytokine induction patterns
upon IFI16 exposure. The fact that IFI16 broadly activates inflammation through TLR4 signal-
ing pathways strengthens the notion that extracellular IFI16 acts as a DAMP capable of pro-
moting inflammation. Fittingly, aberrant IFI16 expression—i.e., overexpression of IFI16 in
otherwise negative cells or IFI16 delocalization to the cytoplasm—has been reported in a num-
ber of inflammatory conditions, such as SLE (skin) [8], psoriasis (skin) [11–13], SSc (skin)
[10], IBD (colonic epithelium) [6,7] and SS (salivary epithelial and inflammatory infiltrating
cells) [14,15,17]. Additionally, aberrant IFI16 expression has been reported in virus-infected
cells [21–23] or cells treated with IFN-γ [46]. Importantly, in some of these and other patho-
logical conditions, we and others have shown that IFI16 exists in a free, extracellular form in
the blood or extracellular milieu [14–16,47]. Particularly, we found that high levels of circulat-
ing IFI16 (� 27 ng/ml) were associated to overall worse clinical parameters in three cohorts of
RA, SS and PsA patients. Notably, among RA patients, circulating IFI16 was more frequently
found in subjects with rheumatoid factor (RF)/anti-CCP-positive serum and significantly asso-
ciated with pulmonary involvement [16]. Furthermore, in SS patients, circulating IFI16 is asso-
ciated with increased prevalence of both RF and glandular infiltration degree [14], while in
PsA patients is associated with elevated C-reactive protein (CRP) levels [19]. The release of
extracellular IFI16 has also been shown by our group in a model of keratinocytes exposed to
UVB radiation [8]. Although the biological rationale of these findings is far from being
completely understood, these observations clearly indicate that the IFI16 protein, whose
expression in the natural setting is restricted to the nuclei of a limited number of cell types,
such as keratinocytes, fibroblasts, endothelial and hematopoietic cells [1], can be released by a
broad spectrum of injured cells, including damaged epithelial cells or the inflammatory cells
recruited at the site of injury, which are known to massively express IFI16. In this setting, as
mentioned above, extracellular IFI16 can act as a DAMP in promoting sterile inflammation
[48]. Accordingly, the exposure of THP-1 cells to conditioned medium from UVB-treated
cells containing the IFI16 protein was able to significantly enhanced IL-6, IL-8 and TNF-α
release when compared to the conditioned medium from UVB-treated IFI16 knockout cells.
Addition of LPS-EB but not that of the weak TLR4-agonist LPS variant further enhanced cyto-
kine induction, while pre-treatment of THP-1 cells with anti-TLR4 antibodies almost abol-
ished the cytokine release. Thus, it is tempting to speculate that, similarly to pathogen-induced
inflammation, binding of extracellularly-released IFI16 to TLR4 can activate both non-
immune and innate immune cells, thus leading to the production of various cytokines and
chemokines responsible for the recruitment of additional inflammatory cells [49].
In agreement with the emerging concept that DAMPs often potentiate their activity by
binding to PAMPs, we demonstrate that the IFI16 proinflammatory activity is significantly
enhanced when the protein is pre-incubated with subtoxic concentration of LPS and then
added to the cells as pre-formed complex. Consistently, this effect is not observed when a trun-
cated variant of IFI16 lacking the LPS-binding domain is used. Despite the fact that IFI16
binds with similar affinity to different variants of LPS, we could only achieve a significant
increase in proinflammatory cytokine release with the strong TLR4 agonists LPS-EB and
LPS-F583. Of note, these LPS molecules when added alone to the cells, even at high doses,
were only able to induce marginally the transcriptional activation of such cytokines. Interest-
ingly, the LPS-F583-derived lipid A DPLA and MPLA, carrying respectively a di- and a mono-
phosphorylated glucosamine dimer, both lacking the sugar inner core, display a remarkably
different ability to enhance IFI16 activity. Although both molecules show the highest affinity
for IFI16 in vitro, only DPLA partially retains the ability to potentiate IFI16 downstream
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signaling. Fittingly, IFI16 binding to Rhodobacter sphaeroides-derived LPS, which is known to
antagonize the response to strong TLR4 activators in human and mouse monocytes [39], did
not affect IFI16 proinflammatory activity. Interestingly, competition binding experiments in
786-O and THP-1 cells suggest that the affinity for TLR4 of either LPS-EB or LPS-RS is higher
than that of IFI16. Indeed, when the cells are exposed to IFI16 and LPS-EB that were not pre-
complexed, the release of proinflammatory cytokines in the culture supernatants is far lower
than that of cells exposed to pre-complexed IFI16/LPS-EB or IFI16 alone. Accordingly, the
binding kinetics revealed by SPR analysis clearly indicated that LPS-EB has a much higher affin-
ity for TLR4 and a very slow kinetics of dissociation when compared to the IFI16 protein alone.
Conversely, the IFI16/LPS-EB complex retains a higher affinity for TLR4 and is not displaced
upon co-treatment with LPS-EB, as attested by the release of cytokines at levels similar to those
observed in the supernatants of cells exposed to the complex alone. Likewise, IFI16/LPS-RS
complex activity is not affected by the simultaneous addition of an equal amount of LPS-RS. In
good agreement with the immunoprecipitation and competition assays, binding kinetics analy-
sis by SPR reveals that LPS-EB, regardless of its overall higher affinity for TLR4/MD2, cannot
compete with the IFI16/LPS-EB complex for binding to the receptor. Indeed, the IFI16/LPS-EB
complex appears to be continuously engaged for TLR4 activation, as indicated by its faster asso-
ciation and dissociation rates. Thus, these data strongly suggest that in vivo i) the proinflamma-
tory activity of IFI16 is enhanced upon its interaction with small amounts of circulating LPS,
and ii) the IFI16/LPS-EB complex has a rapid stimulation turnover on the receptor, successfully
competing with LPS-EB alone and leading to a massive inflammatory response (Fig 9).
Overall, our findings unveil a central role of extracellular IFI16 in triggering inflammation
thanks to its ability to bind to the TLR4/MD2 complex, thereby triggering TLR4/MyD88/NF-
κB signaling. Given that IFI16 is able to form stable complexes with various LPS variants
through interaction of its HINB domain with the lipid A moiety of LPS, we propose a new
pathogenic mechanism regulated by extremely fine-tuned interactions between extracellular
IFI16 and subtoxic doses of LPS, which are known to be present in various pathological set-
tings other than gram-negative infections [50–52].
Materials and methods
Reagents, antibodies, and recombinant proteins
LPS from Escherichia coli O111:B4 (LPS-EB), Porphyromonas gingivalis (LPS-PG) or Rhodo-
bacter sphaeroides (LPS-RS), biotin-labeled LPS from Escherichia coli O111:B4 (biotin-labeled
LPS-EB), detoxified LPS from Escherichia coli O111:B4 (detoxLPS) and polimixin B (PMB)
were all purchased from InvivoGen. LPS from Escherichia coli F583 (LPS-F583), monopho-
sphoryl lipid A from Escherichia coli F583 (MPLA), diphosphoryl lipid A from Escherichia coli
F583 (DPLA) were purchased from Sigma-Aldrich. Bovine serum albumin Fraction V pH 7
(BSA) was purchased from Euroclone.
The following antibodies were used: rabbit polyclonal anti-IFI16 N-term and C-term (pro-
duced as described in [1], mAb anti-human TLR4 (sc-293072, Santa Cruz Biotechnologies),
mAb anti-human TLR4 (sc-13593, Santa Cruz Biotechnologies), mAb anti-human TLR4
(mabg-htlr4, InvivoGen), rabbit polyclonal anti-MD2 (AHP1717T, Bio-Rad), rabbit monoclo-
nal anti-MyD88 (4283, Cell Signaling Technology), mAb anti-NF-κB p65 (sc-8008 X, Santa
Cruz Biotechnologies), PE mouse anti-human CD14 (555398, BD Pharmingen), mAb anti-β-
actin (A1978, Sigma-Aldrich), rabbit IgG-HRP (A6154, Sigma-Aldrich,), mouse IgG-HRP
(NA931V, GE Healthcare), streptavidin-HRP (E2886, Sigma-Aldrich,), mouse IgG-Alexa
Flour 488 (A11001, Thermo Fisher Scientific), normal mouse IgG2a isotype control (sc-3878,
Santa Cruz Biotechnologies).
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Human recombinant IFI16 was produced as previously described [24]. The purified protein
was then processed with Toxin Eraser Endotoxin Removal Kit (GenScript) to remove endotox-
ins, and the final endotoxin concentration was measured using Toxin Sensor Chromogenic
LAL Endotoxin Assay Kit (GenScript). The endotoxin level was always below 0.05 EU/ml.
Purified IFI16 was stored at—80˚C in endotoxin-free vials.
The coding regions of the three IFI16 domains (i.e., PYRIN, HINA and HINB) and of the
IFI16 variant lacking the HINB domain (IFI16ΔHINB) were amplified from full-length
human IFI16 cDNA (isoform b) and cloned in pET30a expression vector (Novagen). The
three domains and IFI16ΔHINB were then synthesized and processed following the same pro-
cedure as that for the full-length protein [24].
GST recombinant protein was expressed using pGEX-4T2 vector and purified according to
standard procedures. The purity of the proteins was assessed by 12% SDS-polyacrylamide gel
electrophoresis. Recombinant TLR4 protein and TLR4/MD2 complex (478-TR-050 and
3146-TM-050/CF, respectively) were purchased from R&D Systems.
Fig 9. Proposed model depicting the inflammatory activities and binding kinetics to TLR4 of LPS and IFI16, alone or in combination. The relative
inflammatory activities, from low to high, are reported in the upper part of the scheme (orange arrow). The relative binding kinetics to TLR4 are reported in
the lower part of the scheme (green arrow). The thickness of the black arrows is directly proportional to the ability of the pathway to induce NF-κB activation.
https://doi.org/10.1371/journal.ppat.1008811.g009
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Pull-down assay, ELISA and competitive ELISA
Biotin-labeled LPS-EB (10 μg) was incubated with 30 μl of streptavidin sepharose high perfor-
mance beads (GE Healthcare) for 3 h at 4˚C. After a washing step, 3 μg of recombinant IFI16,
PYRIN, HINA, HINB, IFI16ΔHINB, or GST were added and incubated O/N at 4˚C. After five
washes with 1X PBS with 0.25% Triton X-100 (Sigma-Aldrich), samples were boiled in sample
buffer containing SDS and β-mercaptoethanol and centrifuged. Supernatants were separated
on a 7.5% or 12% SDS-polyacrylamide gel (Bio-Rad). Gels were stained with Coomassie bril-
liant blue (Serva Electrophoresis GmbH) for protein visualization.
For saturation binding experiments, microtiter plates (Nunc-Immuno MaxiSorp, Thermo
Fischer Scientific) were coated with 2 μg/ml of recombinant IFI16 or 10 μg/ml of BSA or GST
in 1X PBS O/N at 4˚C. After a washing step with 1X PBS and 0.25% Tween 20 (v/v, Sigma-
Aldrich) and blocking step with 1X PBS with 3% BSA and 0.05% Tween 20 for 1 h, increasing
concentrations of biotin-labeled LPS-EB, preincubated with 10 μg/ml of polymyxin B (PMB)
when specified, were added to the wells and incubated for 1 h at room temperature (RT).
Bound proteins were then detected using HRP-conjugated streptavidin. TMB solution
(Thermo Fischer Scientific) was used for color development, and OD was measured at 450
nm. Alternatively, microtiter plates were coated with 10 μg/ml of LPS-EB, LPS-PG, LPS-RS,
LPS-F583, MPLA, DPLA, or detoxLPS in 1X PBS for 24 h at RT. After washing and blocking
for 2 h, increasing concentrations of IFI16, PYRIN, HINA, or HINB were added to the wells,
preincubated with 10 μg/ml of PMB when specified, for 2 h. Anti-IFI16 antibodies against the
N- or the C-terminus of the protein and HRP-labeled anti-rabbit IgG were then added as pri-
mary and secondary antibodies, respectively. The binding was detected as described above.
For whole-cell ELISA, different strains of bacteria (i.e., gram-positive: Staphylococcus
aureus, Staphylococcus epidermidis and Streptococcus pyogenes; gram-negative: Escherichia coli
and Klebsiella pneumonia) were grown in LB medium without antibiotics and, after washing
with 1X PBS, fixed in 0.5% formalin O/N at 4˚C. Subsequently, the bacteria were diluted to an
OD600 of 0.5 and were used to coat microtiter plates O/N at 37˚C. After blocking, increasing
concentrations of IFI16 were added to the wells and incubated for 2 h at RT. Anti-IFI16 anti-
bodies against the N-terminus of the protein and HRP-labelled anti-rabbit IgG were then
added as primary and secondary antibody, respectively, and binding was detected as described
above.
For competitive ELISA, microtiter plates were coated with 1 μg/ml LPS-EB in 1X PBS O/N
at RT. Successively, a constant amount of 2 μg/ml IFI16 was added to the wells in the presence
of increasing concentration of LPS-EB, MPLA or detoxLPS. After incubation for 4 h at RT
under gentle agitation, plates were incubated with an anti-IFI16 N-terminal primary antibody
and an HRP-conjugated anti-rabbit IgG secondary antibody. The binding was detected as
described above. To determine KD constants, saturation binding experiments were performed,
and data were fitted to the Langmuir isotherm equation, which describes the equilibrium bind-
ing of the ligands [53]. Data are reported as sigmoid concentration-response curves plotted
against log concentrations.
Cell cultures, treatments and transfection
Human kidney adenocarcinoma cells 786-O and human leukemia monocytes THP-1 were
obtained from ATCC and grown in RPMI 1640 Medium (Sigma-Aldrich) containing 10% of
fetal bovine serum (FBS, Immunological Sciences) and 1% of penicillin/streptomycin/gluta-
mine solution (PSG, Gibco) at 37˚C and 5% CO2. Wild-type and IFI16-knockout
(U2OS-IFI16-/-) human osteosarcoma cells U2OS were kindly gifted by Dr. Bala Chandrani-
versity of South Florida, FL, USA) [22] and grown in Dulbecco’s modified Eagle’s medium
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(Sigma-Aldrich) containing 10% of FBS and 1% of PSG at 37˚C and 5% CO2. UVB irradiations
were performed as previously described [8]. The resulting cell culture supernatants were cen-
trifuged to remove any cellular pellet and stored at -80˚C for the following experiments.
For treatments, cells were stimulated in complete medium with endotoxin-free IFI16
(25 μg/ml), endotoxin-free IFI16ΔHINB (25 μg/ml), MPLA, DPLA, LPS-F583, LPS-EB,
LPS-RS, alone or pre-complexed by O/N incubation at 4˚C, unless specified otherwise. Addi-
tionally, cells were stimulated with supernatants of untreated or UVB-treated U2OS or
U2OS-IFI16-/- cells alone or preincubated O/N at 4˚C with LPS-EB, or LPS-RS. LPS variants
or lipid A moieties were used at a concentration of 10 ng/ml. All treatments were carried out
at 37˚C and 5% CO2.
For TLR4 neutralization, THP-1 cells were pretreated with 10 μg/ml of anti-TLR4 antibod-
ies for 1 h before treatments.
For TLR4, MD2 or Myd88 gene silencing, cells were transfected with specific human TLR4,
MD2, Myd88 or control siRNAs (Dharmacon, siGENOME smart pool) using DharmaFect1
transfection reagent (Dharmacon). The efficiency of knockdown was confirmed by FACS
analysis and immunoblotting at 48 h after transfection.
FACS analysis
Single cell suspensions were incubated for 30 min on ice with anti-TLR4 (sc-13593), PE-conju-
gated anti-CD14 (555398) or with isotype control diluted in staining buffer (PBS 1% FBS 0.1%
NaN3). To detect TLR4 staining, cells were further washed and incubated for 30 min on ice with
Alexa Fluor 488-conjugated secondary antibody. Cell counts and fluorescence intensity measure-
ments were calculated by Attune NxT Flow Cytometer (Thermo Fisher Scientific). Background
fluorescence was subtracted using unlabeled cells, and channel compensation was performed
using Attune performance tracking beads (Thermo Fisher Scientific). A total of 10,000 events
were recorded. Data were analyzed by FlowJo cell analysis software (BD Life Sciences).
Western blot and immunoprecipitation
Whole-cell extracts were prepared using RIPA lysis and extraction buffer (Pierce) with halt
protease and phosphatase inhibitor (Thermo Fisher Scientific) on ice, and total protein con-
centration was quantified by Bradford Reagent (Sigma-Aldrich) measuring absorbance at 595
nm. Twenty μg of cell extracts, or 30 μl of U2OS culture supernatants were separated by elec-
trophoresis on 7.5% or 12% SDS-polyacrylamide gels (Bio-Rad), transferred to nitrocellulose
membranes, blocked with 10% non-fat milk in tris-buffered saline-tween (TBST), and probed
with specific primary antibodies O/N at 4˚C. After being washed with TBST, membranes were
incubated with specific HRP-conjugated secondary antibodies, and binding was detected by
ECL (Thermo Fisher Scientific, Super Signal West Pico). Expression of β-actin was used as
protein loading control.
Co-immunoprecipitation of TLR4 with interacting proteins was performed using the Dyna-
beads Protein G Immunoprecipitation Kit (ThermoFisher), according to the manufacturer’s
instructions with minor modifications. Briefly, after lysis of treated cells, 20 μg of total cell
extracts were kept as the input control, while 90 μg of total cell extracts were incubated for 1 h
at RT with 2.5 μg of anti-TLR4 antibody previously conjugated with magnetic beads. The
resulting complexes were then washed, eluted, denatured, and subjected to Western blotting as
described above. For DNase-treated cell extracts, DNase I (Sigma Aldrich) was added at a 1:10
dilution and incubated for 15 min at RT. Images were acquired, and densitometry of the bands
was performed using Quantity One software (version 4.6.9, Bio-Rad). Densitometry values
were normalized using the corresponding loading controls.
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Quantitative real time PCR
Quantitative real-time PCR (qRT-PCR) was performed on a CFX96 Real-Time PCR Detection
System (Bio-Rad) as previously described [54]. Total RNA was extracted using TRI Reagent
(Sigma-Aldrich), and 1 μg was retrotranscribed using an iScript cDNA Synthesis Kit (Bio-
Rad). Reverse-transcribed cDNAs were amplified in duplicate using SsoAdvanced Universal
SYBR Green Supermix (Bio-Rad). The glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
gene was used as housekeeping gene to normalize for variations in cDNA levels. The relative
normalized expression after stimulation as compared to control was calculated as fold
change = 2 -Δ(ΔCT) where ΔCT = CTtarget—CTGADPH and Δ(ΔCT) = ΔCTstimulated - ΔCTcontrol.
The primer sequences are available upon request.
Cytokines measurement by ELISA
Cytokines secreted in culture supernatants after treatments were analyzed using human IL-6
DuoSet ELISA and human IL-8 DuoSet ELISA (all from R&D Systems), human TNF-α
Uncoated ELISA and human IL-1β Uncoated ELISA (Thermo Fisher Scientific) according to
the manufacturer’s instructions. Absorbance was measured using a Spark multimode micro-
plate reader (Tecan).
Transcription factor assay
Nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Thermo Fisher Scientific), according to the manufacturer’s instructions. NF-κB binding activ-
ity to a DNA probe containing its binding consensus sequence was measured by Universal
Transcription Factor Assay Colorimetric kit (Merck Millipore). The binding of NF-κB to the
DNA probe was revealed using a specific primary antibody, with an HRP-conjugated second-
ary antibody used for detection with TMB substrate. The intensity of the reaction was mea-
sured at 450 nm. The following biotinylated oligonucleotides were used: sense (biotin): 5’-AT
GACATAGGAAAACTGAAAGGGAGAAGTGAAAGTGGGAAATTCCTCTG-3’; antisense:
5’-CAGAGGAATTTCCCACTTTCACTTCTCCCTTTCAGTTTTCCTATGTCAT-3’.
Surface plasmon resonance analysis
The Biacore X100 (GE Healthcare) instrument was used for real-time binding interaction
experiments. Recombinant TLR4 or TLR4/MD2 complex was covalently immobilized onto
the surface of sensor CM5 (cat # BR100012, GE Healthcare) chips via amine coupling. TLR4
was diluted to a concentration of 10 μg/ml in 10 mM sodium acetate at pH 4.0, while TLR4/
MD2 complex was diluted to a concentration of 20 μg/ml in the same buffer. Both proteins
were injected on CM5 chips at a flow rate of 10 μl/min, upon activation of the carboxyl groups
on the sensor surface with 7-min injection of a mixture of 0.2 M EDC and 0.05 M NHS. The
remaining esters were blocked with 7-min injection of ethanolamine. Taking into account the
ligands (TLR4 or TLR4/MD2) and analytes (IFI16, LPS-EB or IFI16/LPS-EB) molecular
weights (MW) of 70 or 90 kDa, and 90, 10 or 100 kDa respectively, the appropriate ligand den-
sity (RL) on the chip was calculated according to the following equation: RL = (ligand MW/
analyte MW) × Rmax × (1/Sm), where Rmax is the maximum binding signal and Sm corre-
sponds to the binding stoichiometry. The target capture level of the TLR4 or TLR4/MD2 was
of 596.0 or 1,223.9 response units (RUs), respectively. The other flow cell was used as a refer-
ence and was immediately blocked after the activation. Increasing concentrations of endo-
toxin-free IFI16, LPS-EB or IFI16/LPS-EB complex were flowed over the CM5 sensor chip
coated with TLR4 or TLR4/MD2 at a flow rate of 30 μl/min at 25˚C with an association time of
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120 s for IFI16 alone and the IFI16/LPS-EB complex, and 180 s for LPS-EB, and a dissociation
phase of 180 s for IFI16 and IFI16/LPS-EB complex or 600 s for LPS-EB. A single regeneration
step with 50 mM NaOH was performed following each analytic cycle. All the analytes tested
were diluted in the HBS-EP+ buffer (GE Healthcare).
Recombinant IFI16 was covalently immobilized onto the surface of sensor CM5 chips via
amine coupling as done for TLR4 and TLR4/MD2 complex. IFI16 was diluted to a concentra-
tion of 25 μg/ml in 10 mM sodium acetate at pH 4.0. The target capture level of IFI16 was of
1,926.6 response units (RUs). Increasing concentrations of LPS-EB, diluted in HBS-EP+ buffer,
were flowed over the CM5 sensor chip coated with IFI16 at a flow rate of 30 μl/min at 25˚C
with an association time of 180 s and a dissociation phase of 600 s. A single regeneration step
with 50 mM NaOH was performed following each analytic cycle. The KDs were evaluated
using the BIAcore evaluation software (GE Healthcare) and the reliability of the kinetic con-
stants calculated by assuming a 1:1 binding model supported by the quality assessment indica-
tors values.
Statistical analysis
All statistical analyses were performed using GraphPad Prism version 6.00 for Windows
(GraphPad Software, La Jolla California USA, www.graphpad.com). The data are expressed as
mean ± SD. For comparisons between two groups, means were compared using a two-tailed
Student’s t test. For comparisons among three groups, means were compared using one-way
or two-way ANOVA followed by Dunnett’s test. Differences were considered statistically sig-
nificant at a P value < 0.05.
Supporting information
S1 Fig. IFI16 variant lacking HINB domain does not bind to LPS. (A) Domain organization
of the IFI16ΔHINB protein. The numbers represent the amino acid positions based on NCBI
Reference Sequence NP_005522. From the N- to the C-terminal (left to right), IFI16ΔHINB
comprises a pyrin domain, and only one hematopoietic interferon-inducible nuclear protein
with 200-amino-acid repeats (HINA) domain. S/T/P = serine/threonine/proline-rich repeats.
(B) Coomassie brilliant blue staining of pull-down assays performed with 3 μg of recombinant
IFI16ΔHINB, full-length IFI16, or HINB domain in the presence or absence of biotin-labeled
LPS from E. coli O111:B4 (biotin-LPS-EB).
(TIF)
S2 Fig. Expression of TLR4 signaling molecules in 786-O and THP-1 cells. (A) Western blot
analysis of TLR4, MD2 and MyD88 in whole-cell lysates of 786-O cells or THP-1 cells. Immu-
noblot with anti-β-actin antibody was used as loading control. (B) Cell surface expression of
TLR4 and CD14 in 786-O and THP-1 cells (left and right panels, respectively), detected by
flow cytometry using specific antibodies. Blue histograms represent background fluorescence;
red histograms denote TLR4 (upper panels) or CD14 (lower panels) staining. The y-axis repre-
sents the number of cells, while the x-axis represents the level of fluorescence (FL-2) in a loga-
rithmic scale. Images are representative of two independent experiments with similar results.
The percentage of stained cells is reported in each panel. MFI = mean fluorescence intensity.
(TIF)
S3 Fig. Assessment of TLR4, MD2 and MyD88 knockdown upon siRNA transfection. (A)
Upper panel: Western blot analysis of TLR4 and β-actin in whole-cell lysates of 786-O cells or
THP-1 cells transfected with non-targeting siRNA control (siCTRL) or siRNA TLR4 (siTLR4)
at 48 h after transfection. Lower panel: densitometric analysis showing the fold change
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expression of the indicated proteins expressed as the mean from three independent experi-
ments. Error bars indicate SD. (B) Cell surface expression of TLR4 in 786-O and THP-1 cells
(upper and lower panels, respectively), detected by flow cytometry using specific antibodies at
48 h after transfection with siCTRL or siTLR4. Blue histograms represent background fluores-
cence; red histograms denote TLR4 staining. The y-axis represents the number of cells, while
the x-axis represents the level of fluorescence (FL-2) in a logarithmic scale. Images are repre-
sentative of two independent experiments with similar results. The percentage of stained cells
is reported in each panel. MFI = mean fluorescence intensity. (C, D) Upper panels: Western
blot analysis of MD2 (C) and MyD88 (D) in whole-cell lysates from 786-O cells or THP-1 cells
transfected with non-targeting siRNA control (siCTRL) or specific siRNAs—siMD2 and
siMyD88, respectively—at 48 h after transfection. Lower panels: densitometric analysis show-
ing the fold change expression of the indicated proteins expressed as the mean from three
independent experiments. Error bars indicate SD.
(TIF)
S4 Fig. Quantitative RT-PCR analysis of proinflammatory cytokine expression in TLR4,
MD2 and MyD88 knockdown cells. (A-C) qRT-PCR analysis of IL-6, IL-8 and TNF-α mRNA
expression levels in 786-O or THP-1 cells transfected for 48 h with scramble control (siCTRL),
or siRNAs against TLR4 (siTLR4) (A), MD2 (siMD2) (B) or MyD88 (siMyD88) (C). Cells
were then stimulated for 24 h with IFI16 (25 μg/ml), LPS from E. coli O111:B4 (LPS-EB, 10 ng/
ml) or IFI16/LPS-EB complex (preincubated O/N at 4˚C), or left untreated (mock). Values
were normalized to GAPDH mRNA and plotted as fold induction over mock-treated cells.
qRT-PCR data are expressed as mean values of biological triplicates. Error bars indicate SD
(�P< 0.05, ��P< 0.01, ���P< 0.001, ns: not significant; unpaired Student’s t-test for compari-
son of silenced cells vs. their relative control counterpart).
(TIF)
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